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Experimental evidence has demonstrated that several aspects of adult neural stem cells (NSCs), including their
quiescence, proliferation, fate specification and differentiation, are regulated by epigenetic mechanisms. These
control the expression of specific sets of genes, often including those encoding for small non-coding RNAs,
indicating a complex interplay between various epigenetic factors and cellular functions.
Previous studies had indicated that in addition to the neuropathology in Alzheimer’s disease (AD), plasticity-related
changes are observed in brain areas with ongoing neurogenesis, like the hippocampus and subventricular zone.
Given the role of stem cells e.g. in hippocampal functions like cognition, and given their potential for brain repair,
we here review the epigenetic mechanisms relevant for NSCs and AD etiology. Understanding the molecular
mechanisms involved in the epigenetic regulation of adult NSCs will advance our knowledge on the role of adult
neurogenesis in degeneration and possibly regeneration in the AD brain.
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Neural stem cells (NSCs) are present in some areas of
the adult brain that continue to produce new, functional
neurons that are added to existing brain circuits. So-
called neurogenic ‘niches’ are unique tissue microenvi-
ronments that are permissive to the presence of NSCs in
the adult brain [1]. These have now been identified and
characterized in the subgranular zone (SGZ) of the hip-
pocampal dentate gyrus and in the subventricular zone
(SVZ) of the lateral ventricles. In these regions, new
neurons are produced from NSCs throughout life in sev-
eral species including human [2,3]. The NSC niches may
differ strongly from other stem cell niches, e.g. in the
periphery, not only because no neurons are generated
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article, unless otherwise stated.somatic support cell population (micro-/astroglia), vas-
culature, adhesion molecules, growth factors, metabol-
ism etc, are specifically composed in different adult
tissue stem cell microenvironments, providing a “hom-
ing” environment for stem cells [4-14]. Perhaps more
relevant in the context of this review, niches may differ
considerably even within the central nervous system and
may, for instance, influence NSC fate, as stem cells
harvested from the spinal cord, normally destined to
form motor neurons with axons spanning long distances,
form small granule neurons when transplanted into the
hippocampus [7]. Therefore, although it is currently
accepted that a combination of niche signals and cell-
intrinsic programs orchestrate the transition from an
undifferentiated NSC state to a progenitor cell commit-
ted to the neuronal fate [15], epigenetic mechanism such
as miRNAs may play a role in this regulation [16]. This
discussion seems relevant because, specific (NSC) niche
characteristic may condition intrinsic vulnerability of
different stem cells, and specific niche supplement-
ation could be a viable strategy to support proliferation,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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sive discussion of this topic escapes the aim of this review.
The process of adult neurogenesis is also regulated,
e.g. by environmental and hormonal factors like stress,
growth factors, exercise and antidepressant drugs while
alterations have also been observed in neurodegenerative
disorders [19], like epilepsy, stroke [20] or Alzheimer’s
disease (AD), that suggested neurogenesis responds to
these conditions [21]. However, although the neurogenic
capacity in disorders like AD clearly is insufficient or in-
appropriate to compensate for the neuronal dysfunction
or loss [22,23], stimulation of the molecular pathways
that regulate adult neurogenesis may be an attractive
therapeutic or preventative target to boost the brain’s
regenerative capacity.
Multiple intrinsic and extrinsic factors have been iden-
tified, such as growth factors, morphogens, transcription
factors and cell cycle regulators, which control NSC
maintenance in the adult neurogenic niche and their dif-
ferentiation into mature neurons. However, none of
them act in isolation and most function in networks of
signaling molecules that influence each other [15,24,25].
Epigenetic mechanisms are likely key players within
these signaling networks, as DNA methylation, chroma-
tin remodeling and small non-coding RNAs from the
microRNAs superfamily are required for the fine-tuning
and coordination of gene expression during adult neuro-
genesis [16]. The aim of the present manuscript is to
review the involvement and relevance of epigenetic
regulation in adult NSCs and to discuss their possible
role in regulating adult neurogenesis under conditions of
neurodegeneration and AD.
Adult neurogenesis
The maintenance and development of adult NSCs in the
SVZ and SGZ occurs within a highly specialized micro-
environment in which these cells reside, known as the
neurogenic ‘niche’ [26] in which a variety of other cell
types reside as well, including endothelial cells, astro-
cytes, microglia, NSC progeny and mature neurons, that
are all part of the microenvironment of the neurogenic
niche and may contribute to the development of new
neurons. In addition, several extrinsic and intrinsic sig-
naling molecules regulate neurogenesis in these areas
while cells outside the neurogenic niche might also be of
influence through their connections with, and projec-
tions to, cells within the neurogenic niche. The unique
microenvironment of the neurogenic niche is thought to
allow NSCs to proliferate, differentiate, migrate, matur-
ate and integrate in the existing, mature neural network
[15,26,27].
The SGZ and SVZ (or subependymal zone [SEZ]) of
the adult mammalian brain contain different types of
NSCs that give rise to mature neurons. In the SVZ, theprimary NSCs are slow proliferative radial glia-like cells
(type B cells) that express the astrocytic marker glial
fibrillary acidic protein (GFAP). These cells may serve as
the quiescent NSCs of the SVZ and give rise to rapidly
proliferating transit-amplifying progenitor cells (type C
cells). Also splice variants of the GFAP gene, i.e. the
GFAP delta isoform have been associated with stem cells
in this region in rodent and human brain. The type C
cell is seen as an intermediate cell type that generates
neuroblasts (type A cells) that express the neuronal
marker doublecortin (DCX) [28,29]. These cells are able
to migrate from the SVZ through the rostral migratory
stream (RMS) to the olfactory bulb (OB) where they pri-
marily differentiate into GABAergic interneurons. A mi-
nority of the neuroblasts differentiate into dopaminergic
interneurons [3]. The stem cell marker Nestin is expressed
by type A, B and C cells. A fourth cell type lining the
lateral ventricles was found to also express Nestin. These
ependymal cells, or type E cells, exhibit some neural stem
cell characteristics [28].
In the hippocampal SGZ, putative NSCs have also
been identified. Type 1 hippocampal progenitor cells are
radial glia-like cells that express GFAP, similar to the
SVZ type B cells. In addition, they express the stem cell
marker Nestin and the sex determining region Y (SRY)-
box 2 (Sox2) transcription factor. These cells may repre-
sent a quiescent/slow proliferative neural stem cell pool
and are able to produce cells from at least the astrocytic
and neural progeny. Type 2a cells are proliferative non-
radial hippocampal progenitor cells that, in general, do
not express GFAP. Type 2a cells are actively proliferating
and generate other transient neuroblasts with some differ-
ent characteristics known as Type 2b and Type 3 cells,
and their commitment to the neural fate is marked by the
expression of immature neuron markers like DCX and
polysialic acid neural cell adhesion molecule (PSA-
NCAM) [30]. These cells migrate into the inner granule
cell layer (GCL) of the dentate gyrus (DG), where they
start to express calretinin and the granule cell marker
Prox-1 before they differentiate into glutamatergic granule
cells and integrate into the existing hippocampal neuronal
network [24,31].
The important role of the specific microenvironment
in the neurogenic niches for the regulation of NSCs in
the SGZ and SVZ has been shown by several in vivo and
in vitro studies. For example, rat glial progenitor cells
can change to a neuronal fate when transplanted into a
neurogenic region [7], while mouse SVZ neural progeni-
tors committed to the neuronal lineage, changed to glial
differentiation upon transplantation into regions outside
the neurogenic niche [32]. Moreover, neuroblasts can
change their fate and differentiate into oligodendrocytes
upon a change in the microenvironment induced by
demyelination of the corpus callosum [33].
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composed of, and maintained by, several components,
including local cell types, cell signals from more distal
sources, the extracellular matrix and the microvascula-
ture. Of these, the microvasculature has been argued to
be one of the most important structures in maintaining
the functional role of the neurogenic niche [10,34-37],
especially in setting the balance between proliferation
and quiescence of NSCs. Indeed, the SVZ and SGZ
appear to be highly vascularized by a dense network of
specialized capillaries [38]. It has been shown in vitro
that endothelial cells (ECs) can stimulate NSC self-
renewal and neurogenesis through secreted soluble fac-
tors [35,39,40] and that NSCs closely interact with the
microvasculature [10,34,36,41]. Additionally, the blood
flow and hemodynamics of this intricate network affect
NSC proliferation and can also act as a scaffold during
migration [34,42-46]. In addition, microglia, the brain
resident macrophages, have a significant role in the
regulation and maintenance of neurogenesis in the SGZ
[47]. Importantly, microglia may inhibit the proliferation
of neural stem/progenitor cells despite the absence of
inflammatory stimulus [48]. Thus, in addition to fate
determination and cell differentiation, the microenviron-
ment of the neurogenic niche is important for self-
renewal, proliferation, migration and maturation of
NSCs. The exact mechanisms that regulate these
processes within the adult neurogenic niches are now
starting to be identified and interestingly, many of the
mechanisms regulating neurogenesis during embryonic
development, appear to be conserved in adulthood, and
both intrinsic and extrinsic factors important for embry-
onic neurogenesis, including epigenetic regulation, are
also involved in the regulation of neurogenesis in the
adult brain [24].
Epigenetic mechanisms in NSCs
Although the definition of epigenetics is broad and has
been modified over the years, it is currently generally ac-
cepted to refer to changes in gene activity independent
of the primary DNA sequence. In some definitions, only
the modification of activity states inherited across cell
division is considered, consistent with an important role
in the regulation of proliferative cells in the brain [49].
Thus, independently of the genotype, different epigenetic
profiles may result in different phenotypes. Mechanisms
like DNA (hydroxy)methylation, histone tail modifica-
tions and regulation by non-coding RNAs are respon-
sible for these alterations [50]. Alterations in gene
expression patterns induced by these mechanisms may
be more frequent than changes in the hard-coded gen-
etic information, such as genetic mutations. Moreover,
also environmental influences can induce epigenetic
modifications and exert long-lasting effects throughoutthe life-span of an organism. In addition, many of these
epigenetic modifications are heritable through mitoses
and transgenerational effects have been reported too
[16,51-53].
Epigenetic mechanisms play a key role in cell type speci-
fication and the development of most tissues. Consistent
with this concept, adult neurogenesis is under intensive
regulation by epigenetic mechanisms [16] and both tem-
poral and spatial control of gene expression is executed by
epigenetic mechanisms together with other signaling mol-
ecules. This is essential for the regulation of the sequential
stages of neurogenesis. Intrinsic control of neurogenesis
by epigenetic mechanisms within NSCs, and extrinsic
control through epigenetic regulation of gene expression
within non-NSC cells, which form part of the neurogenic
niche, likely contributes to the maintenance of a continu-
ous supply of new neurons in the adult brain [16,51-53].
In particular, epigenetic modifications are capable of con-
trolling (transient) gene repression that are necessary for
NSC pluripotency and proliferation. Furthermore, NSC
fate is determined in part by the permanent silencing of
specific genes through epigenetic mechanisms. Upon cell
fate determination, repression of NSC differentiation-
related genes is e.g. removed and a permanent repression
of the non-cell lineage specific genes is induced. Hence,
expression of cell lineage-specific genes is increased and
NSC cell differentiation is initiated. Individual mecha-
nisms of DNA and histone modifications and non-coding
RNAs are responsible for these changes in gene expres-
sion patterns. In addition, these mechanisms interact and
are capable of influencing each other, forming a complex
network of epigenetic and non-epigenetic regulation of
adult neurogenesis [16,53,54]. Several epigenetic mecha-
nisms that control self-renewal and differentiation of
NSCs have been identified and will be discussed below.
DNA methylation
DNA methylation is one of the most common epigenetic
mechanisms and refers to the addition of a methyl group
to the carbon 5 position of the pyrimidine ring of the
DNA base cysteine, which results in the generation of 5-
methylcytosine (5-mC). DNA methylation is specifically
high at CpG islands and usually results in gene repres-
sion. DNA methyltransferases (DNMT) are the enzymes
that catalyze the reaction of DNA methylation. DNA
methyltransferase 1 (DNMT1) is e.g. important for the
maintenance of DNA methylation over multiple cell di-
visions. After DNA replication, the hemi-methylated
DNA is recognized by DNMT1 and methylation of the
non-methylated DNA strand is induced. DNMT1 thus
maintains DNA methylation through mitoses and is
responsible for the heritability of the DNA methylation
marks. DNMT3a and DNMT3b on the other hand in-
duce de novo DNA methylation at former un-methylated
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regarded as strictly separate, emerging evidence suggests
that these processes overlap far more. Localization of
DNMT1 at the replication fork and its role in DNA
methylation repair suggest a role in replication of DNA
with methylation marks, whereas DNMT3a likely has a
role in DNA methylation repair, similar to its role in
prokaryotes [55,56]. Interestingly, recent studies have
pointed to a role for non-CpG methylation, possibly
mediated by DNMT3a, in embryonic stem cells [57].
DNA methylation and demethylation are dynamic
processes and thought to translate changes in the environ-
ment to changes in gene expression. Recent literature has
highlighted the links between environmental influences
during development/early life, such as temperature, toxic
chemicals, nutrition, tobacco smoke and alcohol and their
consequences on DNA methylation and other epigenetic
mechanisms [58,59]. In turn, DNA methylation directly
and indirectly influences gene expression. Prevention of
transcription factor binding by methylation at gene target
sequences has a direct effect on gene expression. Indir-
ectly, the binding affinity of other transcriptional regula-
tors, including co-activator and co-repressor factors and
complexes is modulated by DNA methylation. Together,
de novo methylation and maintenance of methylation
marks, either directly or indirectly affecting gene expres-
sion, are capable of regulating sequential steps of adult
neurogenesis [51,54].
DNA methylation and adult NSCs
Recent observations have suggested that epigenetic
mechanisms could be sensors of environmental changes
and fine modulators of adult hippocampal neurogenesis
[60]. Enrichment of the environment, a well-known
stimulus of hippocampal neurogenesis, to which exercise
contributes the most, could promote neuronal matur-
ation, possibly through increased methylation activity
[59,60]. In addition, alterations in neurogenesis associ-
ated with pathological conditions of the brain have been
linked to changes in DNA methylation in the brain [60].
The possible mechanisms by which DNA methylation
could influence different stages of adult neural stem cells
in both the SGZ and the SVZ will be discussed.
In vitro analysis of DNMT function in differentiating
NSCs has proven to be a relevant experimental approach
to study the role of DNMTs and DNA methylation in
neurogenesis [61]. Neurosphere formation and inhibition
of differentiation of cultured quiescent NSCs was main-
tained by application of epidermal growth factor (EGF)
and fibroblast growth factor (FGF). Withdrawal from
EGF/FGF supplementation induced their differentiation
and subsequent immunostaining confirmed DNMT1 and
DNMT3a expression and presence of DNA methylation
in undifferentiated NSCs. At the start of differentiation,DNMT1 and DNMT3a were increased but subsequently
decreased upon migration and their late differentiation.
Thus, while high expression was observed in undifferenti-
ated cells, DNMT1 and DNMT3a expression decreases in
the differentiating/migrating NSCs. Importantly, Chroma-
tin immunoprecipitation (ChIP) analysis showed that both
increases and decreases in methylation occur in differenti-
ating NSCs at different loci [61]. This possibly reflects a
combined repression of stem cell maintenance genes and
an activation of cell differentiation genes. Nonetheless, a
role for DNA methylation in NSC differentiation and mi-
gration is further supported by data showing that adminis-
tration of the methylation blocker 5-azacytidine (AZA)
decreases NSC differentiation and migration [61].
The role of DNMT3a in neuronal differentiation has
been further confirmed in the mouse postnatal brain. Wu
and colleagues [62] observed expression of DNMT3a in
both the SVZ and SGZ in the postnatal mouse, while a
more detailed immunohistochemical study found two dis-
tinct types of DNMT3a-immunoreactive cells in the SGZ.
The first type of immunoreactive cells (those with rela-
tively low immunoreactivity) is ubiquitously expressed
throughout the hippocampus, while the second type (dis-
playing high levels of immunoreactivity) was particularly
found in the neurogenic region of the SGZ [63]. Immuno-
histochemical analyses 3 weeks after 5-bromo-2′-deoxyur-
idine (BrdU) administration showed that the high
expressing DNMT3a cells in the SGZ were newborn and
expressed the mature neuron marker NeuN. In agreement
with this observation, knockout of DNMT3a in vivo
results in a profound decrease in postnatal neurogenesis
in both the SVZ and SGZ [63]. Culturing NSCs from
DNMT3a knockout mice confirmed that DNMT3a is
necessary for neuronal differentiation. A 10-fold decrease
in newborn neurons upon differentiation induction was
observed in DNMT3 knockout NSCs, again indicative of
impaired neurogenesis [62]. ChIP analysis revealed that
the DNMT3a targets were enriched among the differen-
tially expressed genes in NSCs obtained from DNMT3
knockout mice. Moreover, the down-regulated genes in
DNMT3a knockout mice were neurogenic genes while
the up-regulated genes were genes involved in astroglial
and oligodendroglial differentiation [62]. Thus, DNMT3a
seems to act in NSCs as a switch that regulates gene
expression towards the non-neuronal lineage when down-
regulated, and towards a neurogenic fate when upregulated.
Indirect regulation of gene expression by DNMTs is
mediated through proteins with methyl-CpG-binding do-
mains (MBDs). MBDs bind to methylated gene promoters,
thereby inhibiting gene expression through blockage
of transcription factor binding or recruitment of other
enzymes that induce transcriptional repression [51].
Similar to the DNMT expression changes described in
the previous paragraph, expression of MBD1 correlates
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MBD1 expression was found in undifferentiated neuro-
spheres. Although a moderate increase in expression
levels was observed at the induction of differentiation,
subsequent down-regulation was seen upon the start of
the migratory phase. This suggests that MBD1 target
genes are highly expressed in the self-renewing NSCs
due to low levels of MBD1 expression. Then, increased
MBD1 expression leads to repression of these genes,
allowing cell differentiation [61]. Since MBD1 expres-
sion is predominantly found in neurons of the adult
brain, MBD1 seems to have a specific role in inducing
or maintaining neuronal differentiation. Indeed, MBD1-
deficient mice have reduced neurogenesis in the post-
natal but not embryonic brain [64]. BrdU analysis
showed that although there were no differences at day
1, the amount of BrdU labeled cells in the MBD1-
deficient mice was significantly decreased 4 weeks after
the BrdU injection. This was accompanied by impaired
neurogenesis and lower cell density in the DG of the
hippocampus. Subsequent phenotypical analysis of the
surviving newborn (BrdU labeled) cells revealed that in
addition to the overall decrease in BrdU-labeled cells,
newborn neurons were significantly more affected than
other, more immature, phenotypes. Additionally, the
percentage of newborn astrocytes was increased [64].
Thus, MBD1 may be important for neuronal differenti-
ation of NSCs and survival of newborn neurons in the
postnatal brain.
The role of MBD1 in adult neurogenesis and NSC
differentiation was confirmed by Li and colleagues [65]
who provided additional information on the molecular
mechanism involved. NSCs isolated from adult MBD1
knockout mice showed increased fibroblast growth
factor 2 (FGF2) expression. Moreover, overexpression of
MBD1 in both MBD1 knockout and wild type NSCs
decreased FGF2 expression. In vitro ChIP analysis con-
firmed the specific binding of MBD1 to the FGF2
promoter while hypomethylation of the FGF2 promoter
in MBD1 knockout mice was observed [66]. Importantly,
all the events that either led to a decrease in MBD1
expression or an increase in FGF2 expression resulted in
reduced neuronal differentiation [65]. This suggests that
neuronal differentiation in the postnatal and adult brain
is dependent on methylation of, and MBD1 binding to,
the FGF2 promoter, which results in its repression.
A second member of the MBD protein family, methyl-
CpG-binding protein 2 (MeCP2) regulates gene expres-
sion through a similar mechanism as MBD1. It binds to
methylated DNA and functions as a transcriptional re-
pressor. Although MeCP2 expression is predominantly
found in neurons, immunohistochemistry on MeCP2
knockout mice brains indicated a different additional
function [67]. Although no difference in the amount ofnewborn neurons was observed in MeCP2 knockout
mice, dendritic spine formation and spine density were
decreased, resulting in delayed and impaired maturation
of the newborn neurons. This was accompanied by a
decreased expression of genes important for synapto-
genesis [67]. Together, it suggests that, in contrast to
a role for MBD1 in early neurogenesis, MeCP2 bind-
ing to DNA methylation marks is important for regu-
lating the expression of genes involved in maturation
of newborn neurons.
MeCP2 may also function to repress non-neuronal
lineage genes and maintain neuronal identity, allowing
proper neuronal differentiation. Kohyama and colleagues
[68] found high expression of MeCP2 in mature hippo-
campal neurons of the adult mouse brain. Subsequent
analysis of the DNA methylation status of different hip-
pocampal cell types revealed high levels of methylation
around the transcriptional start region of the GFAP
gene. Moreover, MeCP2 expression was absent in oligo-
dendrocytes and astrocytes in the hippocampus [68].
Thus, also repression of GFAP expression by binding
of MeCP2 to methylated DNA loci is important for
newborn neuron maturation. Further support for a role
for MeCP2 in maintaining neuronal cell fate was shown
by in vivo transplantation of MeCP2-expressing neural
progenitor cells in non-neurogenic regions [69]. MeCP2
expression allows neuronal differentiation in these areas
where usually astrocytic differentiation is observed. More-
over, expression of a truncated mutant form of MeCP2,
lacking essential domains of the wild type MeCP2, did
not allow NSC neuronal differentiation under astrocytic
differentiation-inducing conditions, indicating that MeCP2
binding to methylated DNA is a key regulatory factor of
this process [69]. Thus, although MeCP2 may not regulate
the initiation of NSC differentiation, it may be important
for neuronal differentiation and neuronal cell fate. Fur-
thermore, while MeCP2 is not required for the production
of immature neurons in the DG, the newly generated neu-
rons, in the absence of MeCP2, exhibit pronounced defi-
cits in neuronal maturation, including a delayed transition
into a more mature stage, altered expression of pre-
synaptic proteins and reduced dendritic spine density,
suggesting that MeCP2 plays a role in other aspects of
neuronal maturation, including dendritic development
and synaptogenesis [67].
Early studies identified mutations in MeCP2 that cause
neurodevelopmental alterations accounting for the ma-
jority of Rett syndrome cases and more recent studies
suggest that MeCP2 plays an important role in brain de-
velopment, aging and in neurological disorders [70]. The
extreme abundance of MeCP2 expression in the brain,
estimated extend to one molecule of MeCP2 for every
two nucleosomes in neuronal chromatin [71] suggesting
that it may play a key role in neurological disorders
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Particularly in the case of Rett Syndrome, the most
common genetic cause of severe intellectual disability in
females, several studies in animal models of the disease
have demonstrated that animal do not develop an irre-
versible condition and that phenotypic rescue may be
possible, highlighting the need to understand the bio-
logical role of MeCP2 and particularly its involvement
in the regulation of DNA methylation in the brain [72].
DNA de-methylation
DNA de-methylation is a complex and not well-understood
process. Recent evidence from studies on the adult
mouse brain indicates that it is a multi-staged process,
starting with the oxidation of 5-mC to form 5-
hydroxymethylcytosine (5-hmC) [73]. Although 5-hmC
can be formed during the process of active demethyla-
tion, it also acts as an important epigenetic mark, that is
functionally different from 5-mC [74]. Interestingly, 5-
hmC is prominent in the brain and plays an important
role in neurogenesis [75]. The oxidation of 5-mC is
executed by ten-eleven translocation (TET) enzymes,
which, after the formation of 5-hmC, continue the oxi-
dation process to subsequently form 5-formylcytosine
(5-fC) and 5-carboxylcytosine (5-caC) [76]. However, a
functional role for 5-fC and 5-caC as independent epi-
genetic markers has still to be elucidated [77]. In addition
to the oxidation of 5-mC and 5-hmC, these marks can
be de-aminated by activation-induced cytidine deaminase
(AICDA) or by an apolipoprotein B mRNA editing en-
zyme, catalytic polypeptide-like protein (APOBEC), result-
ing either in thymine (T) or 5-hydroxymethyluracil
(5-hmU) bases [73]. Regardless of the pathway, the forma-
tion of 5-caC, T or 5-hmU induces a base-to-base mis-
match (i.e. 5-CaC:G, T:G or 5-hmU:G, respectively),
resulting in the removal of the faulty base by thymine or
uracil glycosylases [73,78,79], or the direct conversion
of 5-fC and 5-caC back to C through deformylation or
decarboxylation, respectively [76]. In addition to the afore-
mentioned effector enzymes, the growth arrest and DNA
damage-inducible 45 (Gadd45) family of proteins plays a
pivotal role in the DNA demethylation process [80-83].
Although they do not exhibit enzymatic activity them-
selves, these proteins bind and direct the enzymatic activ-
ity of other proteins, such as cytidine deaminases and
thymine glycosylases, to specific gene promoters.
DNA de-methylation and adult NSCs
Hydroxymethylated DNA immunoprecipitation (hMeDIP)
followed by high-throughput sequencing has recently
started to reveal the genome-wide distribution patterns of
5-hmC in many tissues and cells. Using this technique,
recent reports have suggested a functional role of 5-hmC
during neural differentiation [75,84,85]. Specifically, oneof these studies revealed dynamic changes in DNA hydro-
xymethylation during neural differentiation and identified
differentially hydroxymethylated regions between ESCs
and NPCs [84]. Of interest, 5-hmC is found in most
tissues and its levels seem to be highest in brain, and
enriched in synaptic genes [86].
As described above, the Gadd45 family of proteins
mediates DNA demethylation. This family of proteins
responds to changes in the environment by releasing gene
repression at specific genes through the promotion of
DNA demethylation [16,54,87]. Gadd45b is important spe-
cifically for the sequential steps of activity-induced neuro-
genesis in the adult hippocampus. Gadd45b is expressed
in mature neurons in the hippocampus and neuronal
activity is an important factor in controlling the rate of
neurogenesis [81]. Ma and colleagues [81] studied activity-
induced neurogenesis in the hippocampus of adult
transgenic mice lacking Gadd45b. The increase in NSC
proliferation after electroconvulsive therapy (ECT) ob-
served in the hippocampus of control mice was signifi-
cant decreased in Gadd45b knockout mice. Moreover,
deficits in dendritic growth were observed in Gadd45b
knockout mice, indicating that Gadd45b is important
for neuronal maturation [81]. Methylated DNA immuno-
precipitation (MeDIP) analysis revealed that Gadd45b is
necessary for demethylation at different genes encoding
growth factors involved in neurogenesis, including FGF1
[81], which regulates self-renewal and proliferation of
NSCs similar to FGF2 [54]. These results indicate that
Gadd45b is an immediate early gene expressed in mature
neurons upon neural activity that subsequently regulates
growth factor expression through DNA demethylation.
Secretion of these growth factors, FGF1 specifically, in-
duces increased neurogenesis in the surrounding neuro-
genic niche [81]. Therefore, Gadd45b provides a link
between environmental signals (neuronal activity) and
epigenetic DNA modifications that regulate adult neural
stem cells.
Histone modifications
In many cases, gene expression also depends on DNA
accessibility, which is a.o., determined by chromatin struc-
tural organization. Chromatin is build up of multiple
single nucleosomes consisting of 147 DNA base pairs (bp)
wrapped around a group of proteins, called histones. Sin-
gle nucleosomes contain a total of eight proteins, two cop-
ies of each histone 2A (H2A), histone 2B (H2B), histone
3 (H3) and histone 4 (H4). The amino-acid residues
(N-terminal tails) of these proteins, or histone tails, are
susceptible to multiple post-transcriptional modifications
that regulate their function. Reversible modifications at
the histone tails are established by different mecha-
nisms such as acetylation, phosphorylation, methylation,
ubiquitination and isomerization. The histone modifications
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extensively and may either activate or repress expression of
genes involved in neurogenesis [16,51].
Acetylation and methylation of histone tails is regulated
by different enzymes. Histone acetyltransferases (HATs)
and histone de-acetylases (HDACs) regulate acetylation
levels while histone methyltransferases (HMTs) and his-
tone demethylases (HDMs) regulate methylation. These
enzymes target chromatin loci through specific associa-
tions with proteins that bind to target DNA sequences.
Histone acetylation and methylation at certain loci may
result in gene activation or repression. Histone “marks”
associated with gene activation include acetylation of
lysine 9 and 14 at H3 or tri-methylation of lysine 4 at the
same protein. In contrast, di- or tri-methylation of lysine 9
or 27 at H3 is associated with repression of gene expres-
sion. These histone modifications induce alterations of the
structural configuration of the nucleosome and change
the accessibility of other transcriptional regulators to
DNA. Together, the mechanisms of histone acetylation,
de-acetylation, methylation and demethylation fine-tune
gene expression and can regulate different stages of adult
neurogenesis [16,51,52].
Histone acetylation and adult NSCs
Acetylation of histone proteins is a dynamic process and
especially the removal of acetylation marks by HDACs is
important in neurogenesis [88]. Transcriptional repres-
sion through HDAC activity is essential for adult NSC
proliferation and self-renewal. For example, the orphan
nuclear receptor homologue of the Drosophila tailless
gene (Tlx or NR2E1) regulates NSC self-renewal and
interacts with different HDAC enzymes to regulate gene
expression. Sun and colleagues [89] used ChIP analysis
to show a direct interaction between Tlx and HDAC3,
HDAC5 and HDAC7. These proteins are co-expressed
in cultured adult mouse NSCs, and their expression is
reduced upon NSC differentiation. Furthermore, these
authors found that the cell-cycle regulator p21 was
up-regulated in Tlx knockout mice and ChIP analysis
revealed a common Tlx, HDAC3 and HDAC5 binding
site in the p21 gene promoter. Moreover, treatment of
cultured NSCs with the HDAC inhibitor valproic acid
(VPA) induces p21 expression and increased acetylation
of H4 at the p21 promoter [89]. Thus, both de-
acetylation at the p21 promoter and activation of Tlx are
necessary for inhibition of p21 expression. In vitro treat-
ment of adult NSCs with VPA significantly reduced the
amount of BrdU labeled cells, indicating a decrease in
cell proliferation. Interestingly, both small-interfering
RNA (siRNA) targeting Tlx and HDACs had the same
effect [89]. Thus, the interaction of Tlx with HDAC3,
HDAC5 and HDAC7 seems to be important for the
regulation of genes involved in adult NSC proliferation.A role for histone deacetylation in isolated adult SVZ
NSCs is further supported by interesting observations
done after treating these cells with the HDAC inhibitors
sodium butyrate (NaB) and suberoylanilide hydroxamic
acid (SAHA) [90]. Under these conditions, the authors
observed impaired proliferation that was accompanied
by a profound down-regulation of factors involved in
stem cell maintenance and up-regulation of pro-neural
factors. For example, the expression of Sox2 and the
Notch effector transcription factors Hes1 and Hes5, in-
volved in stem cell maintenance and proliferation, were
down-regulated. Under induced differentiation condi-
tions, SVZ NSCs pretreated with the HDAC inhibitor
SAHA showed decreased glial and oligodendroglial dif-
ferentiation compared to non-treated cells while neur-
onal differentiation was not affected [90]. These results
support the role of HDAC activity in SVZ NSC prolifer-
ation, as was shown before by Sun and colleagues [89]
and provide evidence for an additional role in adult NSC
differentiation.
Increased neuronal differentiation at the expense of
glial and oligodendroglial differentiation has also been
observed in adult hippocampal NSCs treated in vitro
with VPA that increased H3 acetylation levels and
resulted in increased neuronal differentiation, even when
factors favoring non-neuronal cell lineage differentiation
were present [91]. Indeed, profound differences were ob-
served when H3 and H4 acetylation levels were com-
pared between NSCs and their progeny. Initially high H3
and H4 acetylation levels were found in undifferentiated
NSCs and these levels remained relatively high in cells
upon their differentiation into neurons. Lower levels of
H3 and H4 acetylation were observed in cells differenti-
ating into astrocytes or oligodendrocytes, suggesting that
HDAC activity is crucial for NSC fate decisions. Thus,
maintenance of histone acetylation seems important
for neuronal lineage progression of adult NSCs, while
histone de-acetylation appears important for astrocytic
and glial lineage progression.
In vivo, BrdU analysis of the DG of VPA-treated adult
rats showed a marked reduction in proliferation, accom-
panied by a significant increase in BrdU-labeled new-
born neurons. Although astrocytic differentiation was
unchanged, these results confirmed to a certain extent
previous in vitro observations [91]. Similarly, Sun and
colleagues [89] showed e.g. that HDAC expression, and
thus probably histone acetylation, is decreased after
neuronal differentiation of NSCs indicating an important
role for histone acetylation in the regulation of NSC
differentiation. Additional in vitro evidence supporting
this notion was obtained using isolated NSCs from the
adult SVZ [92]. In these experiments, treatment of NSC
for the SVZ cells with SAHA increased their neuronal
differentiation B [92].
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ation in both the adult SGZ and SVZ. HDAC2 is highly
expressed in dividing cells within these areas. Low
HDAC2 expression is associated with NSC quiescence,
while higher expression levels are found in transit ampli-
fying cells and HDAC2 remains present upon differenti-
ation [93]. Deletion of HDAC2 in mice reduces total
HDAC activity in the OB and hippocampal areas accom-
panied by a significant reduction in newborn neuron
numbers and increases in cell death. In contrast, there
was a significant increase in the proliferation rate of
transit amplifying cells, as determined by the amount of
cells in the S-phase of the cell cycle. This increased pro-
liferation but defective neuronal generation in HDAC2
deficient mice is thought to result from the lack of gene
repression by HDACs. The transcription factor Sox2 is
expressed in wild type NSCs and its expression de-
creases upon progression to neuroblasts. However, in
HDAC2 deficient mice, Sox2 expression was observed in
neuroblasts present in the DG. This observation indi-
cates that insufficient histone deacetylation of genes that
are usually repressed by HDAC2 in cells differentiating
towards the neuronal fate, like Sox2, may impair their
maturation but increase their proliferation capacity.
Importantly, although deletion of HDAC2 impaired
neuronal maturation in the adult brain, deletion of
HDAC2 did not change neurogenesis during embryonic
development. Therefore, the requirement for HDAC2-
dependent regulation of proliferation-related genes,
allowing proper neuronal differentiation, seems specific
for adult neurogenesis [93]. Thus, although several epi-
genetic mechanisms regulating embryonic neurogenesis
are conserved into adulthood, also new mechanisms
seem to emerge that regulate adult NSCs specifically.
The activity of several HATs has been studied in vivo
as well [94]. The Querkopf (Qkf) protein is a member of
the MYST family of HATs and it is a transcriptional acti-
vator with histone acetylase activity. During embryonic
development, Qkf is expressed throughout the brain but
its expression is restricted to neurogenic areas in the
adult brain. In the SVZ of the adult brain Qkf is
expressed in type A, B and C NSCs. A 90% reduction in
Qkf transcription is observed in mice carrying hypo-
morphic Qkf alleles. This reduction is associated with
decreased NSC proliferation and alterations in the pro-
portions of the cell types derived from them, suggesting
that defective neurogenesis in the OB of adult Qkf-
deficient mice may result from a decrease in the prolifer-
ative NSC population and alterations in the cell progeny
derived from it [94]. In addition, isolation of SVZ NSCs
from Qkf-deficient mice showed impaired neuronal dif-
ferentiation in vitro, while Qkf overexpression increased
neuronal differentiation [94]. This indicates that the
level of Qkf, and presumably of Qkf-mediated histoneacetylation, regulates neuronal differentiation of adult
NSCs in the SVZ. A similar impairment in neuronal dif-
ferentiation was observed in isolated cells in vitro [94].
In conclusion, these results suggest a role for histone
acetylation in neuronal differentiation, in line with previ-
ous studies where increased acetylation induced by
HDAC inhibition increases neuronal differentiation.
Histone methylation and adult NSCs
Adult neurogenesis is under tight epigenetic control of his-
tone methylation that is regulated by two antagonistic com-
plexes. The Polycomb-group (PcG) protein complex, that
promotes histone 3 lysine 27 tri-methylation (H3K27me3),
and the Trithorax-group (TrxG) protein complex, that pro-
motes histone 3 lysine 4 tri-methylation (H3K4me3). Both
are part of an evolutionarily conserved chromatin remodel-
ing system that silences or activates gene expression, re-
spectively. Together, these histone methylation events
regulate the establishment and maintenance of different
cell states in NSCs [51,54,95].
The PcG member B lymphoma Mo-MLV insertion
region 1 homolog (Bmi-1) is required for postnatal NSC
self-renewal. In vitro, Bmi-1 overexpression in NSCs iso-
lated from the adult mouse SVZ increases neurosphere
formation and self-renewing capacity of these cells [96].
Moreover, when differentiation was induced after five
culture passages, the differentiation capacity of wild type
NSCs was very low, while Bmi-1 overexpressing NSCs
produced both glia and neurons under the same experi-
mental conditions. Both immature and mature neuronal
markers were expressed in these cultures. In vivo over-
expression of Bmi-1 showed a similar increase in NSC
proliferation in the SVZ and RMS [96]. This indicates
that increased H3K27me3 induced by Bmi-1 overexpres-
sion could affect the expression of genes important for
NSC proliferation and differentiation both in vitro and
in vivo. In support, proliferation within the SVZ is de-
creased in adult Bmi-1 deficient mice [97]. In addition,
NSCs isolated from Bmi-1 deficient mice showed de-
creased proliferation and self-renewal capacity in vitro,
compared to wild type cells [97]. Although direct histone
methylation measurements were lacking in this study,
Bmi-1 is part of the PcG complex that catalyzes H3K27
tri-methylation, indicating that impairment of repressive
histone methylation due to loss of Bmi-1 may be respon-
sible for the results observed. Interestingly, Bmi-1 defi-
ciency has been associated with increased expression of
cell-cycle inhibitors such as p16 (Ink4a) and p19 (Arf ),
and accurate repression of these genes by Bmi-1 repre-
sents a critical mechanism by which Bmi-1 drives NSC
self-renewal [98].
Recent observations have shown that the TrxG member
mixed-lineage leukemia 1 (Mll1) is required for adequate
neurogenesis progression [99]. Mll1-deficient NSCs purified
Fitzsimons et al. Molecular Neurodegeneration 2014, 9:25 Page 9 of 21
http://www.molecularneurodegeneration.com/content/9/1/25from the SVZ survived, proliferated and efficiently differen-
tiated into glial lineages but their neuronal differentiation
was impaired. In Mll1-deficient cells, the expression of the
early proneural Mash1 and gliogenic Olig2 expression was
preserved, but Dlx2, a key downstream regulator of SVZ
neurogenesis, was not detected. In line with these observa-
tions, neurogenesis could be rescued by Dlx2 overexpres-
sion, demonstrating the crucial role of Mll1 in controlling
Dlx2 expression and thus progression towards a neuronal
phenotype. Indeed, ChIP analysis showed direct interac-
tions of Mll1 with the Dlx2 gene promoter and Dlx2-
regulatory sequences were bivalently marked by both
H3K4me3 and H3K27me3 in Mll1-deficient cells. This bi-
valent histone methylation pattern resulted in the Dlx2
gene failing to properly activate, demonstrating the rele-
vance of epigenetic regulation of Dlx2 in controlling adult
neurogenesis in the SVZ [99]. In vivo, Mll1 deficiency de-
creases the size of neurogenic regions in the postnatal brain
including neuronal number, with a sharp decrease in the
amount of newly formed neurons in the OB. However, in
the SVZ, DCX positive cells are increased in number, indi-
cative of an impaired migratory capacity. Moreover, con-
tinuous expression of transit-amplifying cell characteristics
in these DCX expressing neuroblasts suggests that gene re-
pression upon differentiation was impaired, which may pro-
vide a plausible explanation for the impaired differentiation
and migration observed in Mll1 deficient neuroblasts [99].
Thus, Mll1 expression and histone methylation catalyzed
by the TrxG complex seems to be an important regulator
of postnatal neurogenesis in the mouse SVZ.
Wu and colleagues [62] have demonstrated the ability of
DNMT3a to interact with histone methylation. Whereas
DNA methylation at promoter regions generally prevents
the binding of transcription factors and inhibits gene
expression, Wu and colleagues [62] showed that DNMT3a
activity correlates with increased expression of neurogenic
genes. The increased expression of these neurogenic genes
seems to be mediated through an interaction between
DNA methylation and histone methylation. ChIP analysis
showed that loss of DNMT3a increased binding of the
PcG complex Polycomb repression complex 2 (PRC2) to
DNMT3a targets, which was accompanied by increased
H3K27me3 levels and decreased target gene expression.
This effect was specific for DNMT3a targets since binding
of PCR2 and H3K27me3 levels did not change at non-
DNMT3a targets. In support of this conclusion, restoration
of DNMT3a activity functional rescued by introduction of
wild type DNMT3a reversed the abnormally increased
H3K27me3 levels and PRC2 occupancy at down-regulated
DNMT3a target genes in the DNMT3a knock-out NSCs.
These results indicate that methylation by DNMT3a may
antagonize the repression of gene activity mediated by
PcG complex binding and H3K27me3 establishment
in NSCs [62] and support a function for DNMT3a inthe repression of genes regulating NSC self-renewal
and activation of neurogenic genes, thereby regulating
neuronal differentiation.
MicroRNAs
A third epigenetic mechanism capable of controlling the
neurogenic process involves non-coding RNAs. Tran-
scription of non-coding DNA regions generates several
classes of non-coding RNAs. Small non-coding RNAs,
such as siRNAs, small nucleolar RNAs (snoRNAs), piwi-
interacting RNAs (piRNAs), small modulatory RNAs
(smRNAs), repeat-associated small interfering RNAs
(rasiRNAs), transcription initiation RNAs (tiRNAs),
small double-stranded RNA (dsRNAs) and microRNAs
(miRNAs) are all expressed in the brain [100]. More spe-
cifically, the 21–25 nt long miRNAs have been linked to
the regulation of gene expression during adult neurogen-
esis, acting post-transcriptionally, usually through their
binding to the 3′ un-translated regions (3′ UTR) of their
target mRNAs. In most cases, the binding of a miRNA
to an imperfect complementary gene transcript results
in the repression of translation of the target mRNA.
Since most miRNAs form imperfect base-pairs with their
mRNA targets, a single miRNA is capable of regulating
a large number of different genes. About 2019 unique
human miRNAs and 1265 mature miRNAs in mice have
been identified to date [101].
Modulation of gene expression of different signaling
molecules involved in the neurogenic process, as well as of
other epigenetic mechanisms present in the brain, impli-
cate an important function of miRNAs in adult neurogen-
esis. Since a number of excellent reviews [51-54,95,100]
have highlighted the roles of miRNAs in the regulation of
gene expression in NSCs, we present in the next section
only a short overview of the published data.
MicroRNAs and adult NSCs
Functional studies of different miRNAs demonstrate their
importance for different stages of adult neurogenesis. Let-
7b, miR-9, miR-106b, miR-137, miR-184 e.g., are involved
in the proliferation of adult mouse NSCs. An additional
role for miR-9, miR-34a, miR-137 and miR-184 as well as
for miR-124 have been found in neuronal differentiation.
Moreover, miR-137 is involved in synaptogenesis and
miR-132 regulates both synaptogenesis and neuronal net-
work integration of adult mouse NSCs [100], while miR-
34a and miR-125b modulate dendritogenesis and spine
morphology [102]. We here focus on well-studied miR-
NAs with a key role in adult neurogenesis, e.g. miR-34a,
that was recently implicated in aging and neurodegenera-
tion in Drosophila, is an essential miRNA, particularly in
the developing brain [103].
MiR-34a regulates neuronal differentiation via Notch
signalling by repressing the γ-secretase inhibitor numb
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sion of miR-34a increases neurite elongation of mouse
NSCs [105]. MiR-34a modulates the expression of syn-
aptic targets including synaptotagmin-1 and syntaxin-1A
while its target SIRT1 may mediate the effects on neurite
elongation. Overexpression of miR-34a further alters
hippocampal spinal morphology, and subsequent elec-
trophysiological function of dendritic spines [106].
MiR-125b is another brain-enriched miRNA, abundantly
expressed in the foetal hippocampus under physiological
circumstances [107-109]. MiR-125b levels increase during
in vitro differentiation of embryonic stem cells [110].
Moreover, miR-125b is downregulated in cerebellar neur-
onal progenitors, increasing with differentiation, thereby
allowing cell maturation and growth inhibition [111].
MiR-125b functions by suppressing Nestin expression,
thus modulating proliferation and differentiation of
neural stem and progenitor cells, as well as migration
of the cell types derived from them [112]. Furthermore,
the regulatory function of miR-125b on dendritogenesis
could be partly attributed to the fact that a subset of its
repressed targets, such as itchy E3 ubiquitin protein
ligase (ITCH) and diacylglycerol O-acyltransferase 1
(DGAT1), in turn antagonize neuronal genes in several
neurogenic pathways. Therefore, their translational re-
pression by miR-125b suggests a positive role for miR-
125b in neurite outgrowth and differentiation [113].
MiR-132 is a brain-enriched miRNA centrally involved
in the regulation of neuronal plasticity upon neuronal
activation [114]. Overexpression of miR-132 in cultured
hippocampal neurons demonstrates that miR-132 modu-
lates short-term synaptic plasticity [115], while overex-
pression in vivo triggers an increase in dendritic spine
density [116]. MiR-132 has been proposed to differenti-
ate neuronal stem cells specifically into dopaminergic
neurons via a direct posttranscriptional repression of
the nuclear receptor subfamily 4, group A, member 2
(NR4A2, also known as Nurr1) [117]. MiR-132 is also
required for normal dendritic maturation in newborn
neurons in the adult hippocampus and indirectly partici-
pates in CREB-mediated signaling [118]. More specific-
ally, CREB-induced transcription of miR-132 results in a
decrease of MeCP2 expression and a subsequent de-
crease in brain-derived neurotrophic factor (BDNF) due
to de-repression of REST [119]. On the other hand,
miR-132 expression is greatly enhanced via the ERK1/2
pathway by neurotrophins, such as BDNF, thus forming
a negative regulatory feedback loop [120].
Although MiR-124 is abundantly expressed in the
adult brain, its expression in different isolated cell types
of the adult mouse SVZ indicates an important role in
neuronal differentiation. While expression was absent in
both type B and C cells, miR-124 expression was ob-
served at the transition from type C transit amplifyingcells to type A neuroblast cells. Upon further differenti-
ation, expression increases [121]. Separation of the
neuroblast population based on their cell cycle stage
indicated by a DNA dye shows increasing miR-124 levels
from S/G2-M phase to G0/G1 phase. Thus, miR-124 ex-
pression increases at the transition from type C to type
A cells and furthermore increases upon cell cycle exit of
the neuroblasts. An in vitro knock-down of miR-124 de-
creases the amount of neuroblasts exiting the cell cycle,
while the amount of proliferating type C and A cells in-
creases. This indicates that miR-124 expression is specif-
ically important for the transition from proliferating
neuroblasts to differentiated neuroblasts that have left
the cell cycle. Computational analysis of miR-124 targets
identified the Sox9 transcription factor, that is involved
in NSC self-renewal, the Notch-ligand Jagged-1 and the
transcription factor Dlx2. MiR-124 targeting of Sox9
was studied in more detail [121]. While differentiating
NSCs expressing miR-124 still express Sox9 mRNA,
Sox9 protein expression is repressed. This observation
supports post-transcriptional repression of Sox9 by miR-
124 at the transition from proliferating to differentiating
neuroblast cells.
Similarly, repression of mRNA translation by miR-9 is
important for neuronal differentiation. Expression of this
miRNA has been observed in the neurogenic regions of
the brain [122]. Although different miR-9 targets have
been identified to regulate this process, miR-9 expres-
sion, like miR-124, increases upon neuronal differenti-
ation. Functional analysis of miR-9 in isolated adult mice
forebrain NSCs supports its role in neuronal differenti-
ation. While miR-9 overexpression reduced NSC prolif-
eration and increased neuronal differentiation, miR-9
knock-down showed opposite effects. MiR-9 overexpres-
sion was accompanied by a reduction in expression of
the Tlx receptor that is involved in NSC maintenance,
as discussed before. ChIP analysis showed that miR-9
targets Tlx at its 3′UTR, inducing translational inhib-
ition. MiR-9 thus negatively regulates Tlx expression and
reduces NSC proliferation but increases neuronal differ-
entiation [122]. Another miRNA targeting Tlx is Let-7b.
Increased expression has been observed upon neuronal
differentiation similar to miR-124 and miR-9. A knock-
down of Let-7b enhances NSC proliferation and decreases
neuronal differentiation, while again overexpression shows
the exact opposite [123].
Additional functions resulting from the combined ac-
tions of miR-9 and miR-124 in neuronal fate progression
were demonstrated in a reprogramming study of isolated
human fibroblasts [124]. Here the authors showed that
miR-9 and miR-124 are capable of inducing a neuronal
fate conversion. Combined expression of these miRNAs
with transcription factors important for neurogenesis
enhanced the rate of conversion of these cells into the
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creased maturation of the differentiated neurons. Strik-
ingly, neurogenic transcription factor expression alone
did not induce the conversion of these fibroblast cells
into the neuronal fate [124]. Thus, the combination of
miR activity regulating gene translation and the regula-
tion of gene expression by different transcription factors
act together to induce a neuronal fate conversion. This
study emphasizes the importance of these miRNAs in
the induction of neuronal fate.
Other miRNAs regulate different stages of adult neuro-
genesis acting on different targets during the process of
neuronal maturation [125]. Adult mice hippocampal
NSCs were isolated and used to identify lineage specific
miRNAs. To this aim, miRNA expression patterns of
differentiated astrocytes and neurons were compared by
qPCR and miRNAs specifically enriched in the neuronal
lineage were further investigated. Following this approach,
miR-137, specifically enriched in neurons, was implicated
in neuronal maturation. In vivo overexpression of this
miRNA in newborn neurons of the adult mouse DG
decreased their dendritic complexity, dendritic spines and
length of the maturated neurons. This indicates that the
maturation process in the miR-137 overexpressing cells
was impaired. The increase in miR-137 seems to disrupt
the sequential events of neuronal maturation leading to
structural alterations. In vitro analysis of miR-137 expres-
sion confirmed enrichment in dendrites of differentiated
neurons, indicating a role in development of these den-
drites as was observed in vivo [125]. Underscoring its
importance in neurogenesis, miR-137 targets the mind
bomb 1 (MIB1) protein, an ubiquitin ligase essential in
neurodevelopment [125] and miR-137 post-transcriptionally
represses the expression of Ezh2, a histone methyltransfer-
ase and Polycomb group protein, resulting in a global
decrease in histone H3K27me3. Furthermore, miR-137 is
epigenetically regulated by MeCP2, a DNA methyl-CpG-
binding protein, a mechanism we discussed before and in
the next section [126]. Although in-depth mechanistic
studies of miRNA functioning will have to be done in
order to understand the complete regulation network,
overall, the studies discussed in this section suggest that
miRNAs are capable of regulating NSCs at different
stages. Subsequent identification of miRNA targets might
contribute to unravel the control of neurogenesis at the
molecular level.
Epigenetic interplay in the regulation of adult NSCs
In addition to gene expression regulation, miRNAs also
interact with, and regulate epigenetic mechanisms such
as DNA methylation and histone modifications, with
possible consequences for AD [127]. These interactions
are considered central to understanding the regulation
of gene-expression networks during neurogenesis. Forinstance, two epigenetic regulators that have been found
to interact are MBD1 and miR-184. MBD1 knock-out
in vivo and acute knock-down of MBD1 in vitro induce
significant increases in miR-184 expression [128]. In con-
trast, in vitro overexpression of MBD1 decreases miR-184
expression. Indeed, the genomic region surrounding the
miR-184 gene contains high CpG-rich areas and ChIP ana-
lysis of wild type NSCs showed MBD1 binding surround-
ing the miR-184 genomic area. The increase in miR-184
expression observed in MBD1 deficient NSCs was accom-
panied by increased H3K4me3 and H3K9Ac and decreased
H3K27me3 surrounding the miR-184 genomic region
[128]. These results indicate that MBD1 may regulate miR-
184 expression by interacting with histone modification
mechanisms. MBD1 seems to antagonize H3K4me3 and
thereby inhibit miR-184 expression using a mechanism
different from the DNMT3a-mediated antagonism of
H3K27me3 discussed in previous sections [62]. Overex-
pression of miR-184 showed repression of astroglial and
neuronal lineage genes and decreased differentiation of
adult NSCs in vitro. Moreover, NSC proliferation and neu-
rosphere formation were increased. In vivo, BrdU analysis
after miR-184 overexpression in the DG indicated an
increase in NSC proliferation while the percentage of
differentiating cells was decreased [128]. As Zhao and col-
leagues [64] and Singh and colleagues [61] showed before,
MBD1 regulates neuronal differentiation. These results
suggest that the regulation of neuronal differentiation
mediated by miR-184 may involve its regulation by MBD1
and modifications of histone marks.
Thus, the interplay between MBD1, miR-184 and his-
tone modification mechanisms seem to maintain, at least
in part, the balance between NSC proliferation and differ-
entiation. Moreover, as discussed before, MBD1 targets
FGF2, important for NSC proliferation [65]. Repression of
this growth factor by MBD1 is necessary for proper neur-
onal differentiation, adding an additional player within this
molecular network regulating neuronal differentiation of
adult NSCs. In support of this hypothesis, activity
dependent DNA demethylation by Gadd45b increases
expression of a growth factor similar to FGF2 [81]. Based
on the previous discussion, these complex interactions
between epigenetic mechanisms could explain, at least in
part, the release of repression on proliferation/differenti-
ation genes through histone modifications and decreased
MBD1 binding due to DNA demethylation.
Alzheimer’s disease
AD is a neurodegenerative disorder characterized by
severe and progressive memory deficits, accompanied by
atrophy of specific brain regions and extensive neuro-
pathology and gliosis. It is initially identified by impaired
episodic memory that worsens with the accumulative
neurodegeneration [129]. The disease is characterized by
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from the proteolysis of the amyloid precursor protein
(APP), which forms the main components of extracel-
lular senile plaques, and the accumulation of intra-
cellular neurofibrillary tangles (NFTs), which mainly
consist of microtubule-associated protein tau, that is
hyperphosphorylated and organized in paired helical
filaments [130].
AD and neurogenesis
Several studies have shown that, in addition to age, neu-
roinflammatory and neurodegenerative processes have a
pronounced influence on adult neurogenesis [131]. In
AD, biochemical and histological approaches have pro-
vided contradictory results when comparing animal
models and studies on human brain. Studies in AD were
not only hampered by obtaining standardized human
tissue of sufficient quality, but also by the lack of reliable
makers to identify the different stages of the neurogenic
process in post-mortem tissue. Although specialized
markers from the tumor field have been promising,
methodological issues of post-mortem delay, specificity
and fixation are not trivial and so far, only a few studies
have reported changes in proliferation or young neur-
onal markers in AD brain. One report showed increases
in various immature neuronal markers in senile AD, sug-
gesting that neurogenesis could be increased in late AD
[132]. In a study in younger, presenile patients, these re-
sults could not be replicated [133]; although a significant
increase in the number of Ki-67+, proliferating cells was
found, these cells were mostly associated with glia and
the vasculature (Marlatt et al., submitted 2014). Later
studies have used markers like Musashi-1, nestin and
PSA-NCAM to show that neurogenic abnormalities in
AD differ between phases and areas of neurogenesis and
stages of AD: while hippocampal stem cells (Musashi-1)
decrease, proliferation increases and differentiation/mi-
gration phase as well as axonal/dendritic targeting (DCX
and β-III-tubulin) remain unchanged, suggesting an
attenuation of stem cells together with compensatory
increases in proliferation that, however, does not result
in increases in differentiated new neurons in AD [134].
Similar findings exist on microtubule-associated protein
isoforms some of which represent immature neuronal
markers, like the MAP2c isoform. Another study re-
ported a decrease in DCX- and sex determining region
Y-box 2 (Sox2)-positive cells in human AD but an
increase in bone morphogenetic protein 6 (BMP6) levels
that was also found in APP transgenic mice, suggesting
a role in defective neurogenesis in AD [135]. Collect-
ively, these findings suggest that proliferating cells in the
AD dentate gyrus do not become mature neurons
[136-138]. Also, it is yet clear whether this represents a
compensatory mechanism in response to neurodegenerationor an effect induced by the medication the patients
received before death.
On the other hand, a decline in proliferation in the SVZ
has also been shown in AD [139,140]. More recently,
Perry and colleagues [134] observed that while hippocam-
pal stem cells decrease, proliferation increases and differ-
entiation/migration phase as well as axonal/dendritic
targeting remain virtually unchanged, suggesting a de-
crease in NSC numbers accompanied by compensatory
increased proliferation which again, may not result in
increases in migratory neuroblasts and/or differentiated
neurons in AD. Additionally, they suggested that neuro-
genic abnormalities in AD would differ between phases
and areas of neurogenesis and stages of AD.
Transgenic mice expressing human APP and presenilin-
1 (PS1) genes with familial AD associated mutations,
exhibit early and progressive accumulation of Aβ, possibly
resulting in compromised neocortical synaptic plasticity
and synaptic dysfunction, traits similar to those observed
in AD patients [141]. In most of these experimental
models decreased proliferation, differentiation and sur-
vival have been described but this depends on the stage of
the disease and the extent of pathology [21]. Moreover,
decreased neurogenesis and increased astrogenesis were
found in APOE knock-in mice [142]. Interestingly, mice
solely expressing human mutated PS1 presented with an
age-related increase in hippocampal granule cell numbers,
suggesting a beneficial role for the PS1 gene on neurogen-
esis [143]. In another study using PS1/PS-2 double-
knockout mice, robust AD like pathology is found [144],
notably in absence of beta-amyloid deposition, and the au-
thors observed enhanced neurogenesis in the early stages
of neurodegeneration. However, this increase could not
be detected anymore at later disease stages, possibly
due to a decreased survival of the newly generated neu-
rons [144]. Because these dynamic changes in neuro-
genesis were correlated with the severity of neuronal
loss in the DG, the authors concluded that neurogen-
esis may work as a self-repairing mechanism to com-
pensate for neurodegeneration.
Interestingly, a recent study designed to study the effect
of different variants of hAPP on morphological and func-
tional parameters during GC development found that
some hAPP cleavage products, such as the β-C terminal
fragment (β-CTF) C99, induced a substantial reduction in
glutamatergic connectivity in 21 day-old newborn neurons
in the SGZ [145], a period of active dendritic growth and
synaptogenesis [146]. Importantly, the strength of gluta-
matergic inputs recovered in mature, 35-day-old neurons
and the delay in glutamatergic synaptogenesis observed by
the authors was paralleled by a decrease in dendritic
length with no changes in spine density, suggesting that
hAPP may be able to affect dendritic development under
certain circumstances [145].
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tion suggests that a better comprehension of the signaling
mechanisms that modulate neurodegeneration and neuro-
genesis in AD could provide us with new candidate targets
for future studies on AD neurobiology and treatment.
AD and epigenetics
The etiology and pathophysiology of AD, including aber-
rant processing of amyloid and tau, are not well under-
stood. Recently, some studies have pointed out that
epigenetic changes could be involved in these processes
that will be discussed below.
AD and DNA methylation
Initial epigenetic investigations pertaining to AD focused
on DNA methylation of the APP gene and illustrate the
complexity and difficulty of investigating the epigenetics
of the multifactorial and heterogeneous affliction that is
AD. West and colleagues [147] observed hypomethyla-
tion of the APP gene promoter in an AD patient,
whereas Barrachina and colleagues [148] did not find
any significant AD-related abnormalities in methylation
of the APP promoter region. They also did not find any
abnormal methylation patterns in the MAPT and PS1
genes, even when looking at different stages of the
disease. While this group did report the presence of high
and low methylated CpG sites in and around the APP
promoter region, Brohede and colleagues [149] found no
methylation at all at the investigated CpG site in the
APP gene. Interestingly, Tohgi and colleagues [150] have
found an age-related decrease in cytosine methylation in
the promoter region of the amyloid precursor protein
(APP) gene in the human cerebral cortex. Additionally,
they observed abnormal cytosine methylation in the pro-
moter region of the tau gene in the aged human cerebral
cortex [151].
Although it remains to be elucidated whether the APP
gene is specifically regulated by DNA methylation or
not, strong evidence suggests that DNA methylation is
disrupted in AD. Pioneering studies have shown that S-
adenosylmethionine (SAM), a methyl donor crucial for
DNMTs activity, is severely reduced in AD [152]. Later,
the relation of this finding with actual DNA methylation
was corroborated by the detection of decreased global
DNA methylation in the AD brain [153,154]. Additional
studies have specifically investigated the hippocampus,
one of the brain regions strongly affected by AD and
found increased levels of 5-mC [155] and DNMT3a [63]
in the hippocampus of aging mice, but reduced 5-mC
levels in APP/PS1 transgenic mice (Chouliaras et al.,
submitted, 2014) and in the hippocampus, entorhinal
cortex and cerebellum of AD patients [156,157]. Fur-
thermore, DNA methylation in AD seems to particularly
involve DNMT3a, as the presence of a tagSNP in theDNMT3a gene correlated with cognitive decline in MCI
patients (Chouliaras et al., submitted 2014).
Remarkably, Aβ itself has been shown to affect DNA
methylation [158]. Aβ seems to induce global DNA
hypomethylation, while its effect on specific genes is
more complex. Indeed, the NEP gene seems to be hyper-
methylated under influence of Aβ, repressing its tran-
scription [158]. This interaction between Aβ and NEP
might be of crucial importance for AD pathology, as the
NEP gene encodes for neprilysin, one of the primary
enzymes involved in Aβ degradation.
Although the consequences of aberrant DNA methyla-
tion associated with AD remain to be fully elucidated,
some affected genes have been identified. Siegmund and
colleagues [159] found SORBS3 to be hypermethylated,
while S100A2 was hypomethylated, possibly reflecting an
acceleration of the age-related changes in the normal brain.
SORBS3 encodes a cell adhesion molecule and decrements
in its expression seem to contribute to the synaptic abnor-
malities associated with AD [160]. Increased expression of
S100A2, which encodes a calcium binding protein, is asso-
ciated with corpora amylacea formation [161]. In addition,
Scarpa and colleagues [162] showed that PS1 was hypo-
methylated. As the protein encoded by PS1 is part of
the enzymatic complex responsible for Aβ production,
increased PS1 expression may enhance Aβ formation. Of
note, one study comparing human postmortem frontal
cortex genome-wide DNA methylation profiles between
late-onset AD and 12 cognitively normal controls found
widespread, albeit modest, discordant DNA methylation
independent from DNA methylation changes with age [163].
AD and DNA hydroxymethylation
DNA hydroxymethylation is not as well studied as DNA
methylation, and neither in relation to AD. Nevertheless,
studies of DNA hydroxymethylation in the hippocampus
suggest a pattern similar to DNA methylation: increasing
levels with normal aging [155,164,165], but strongly de-
creased levels in APP/PS1 mice (Chouliaras et al., submit-
ted 2014) and AD patients [156,157]. Interestingly, Münzel
and colleagues showed that levels of 5-hmC increase with
age [164]. The importance of DNA hydroxymethylation in
AD is further stressed by the discovery of a single nucleo-
tide polymorphism (SNP) in the TET1 gene, which protein
catalyzes the conversion of 5-mC into 5-hmC, associated
with late onset AD [86,166]. While the functional impact
of changes in DNA hydroxymethylation associated with
AD largely remain to be explored, the findings discussed in
this section further support the notion of a widespread
failure of the epigenetic regulatory system in AD.
AD and histone modifications
Besides DNA methylation, a growing body of evidence
suggests that alterations in histone acetylation are
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pathogenesis. Histone acetylation is significantly lower in
the temporal lobe of AD patients compared to aged con-
trols [167]. Furthermore, Marques and colleagues [168]
showed that increased levels of beta-secretase 1 (BACE1),
a protease that cleaves APP in the amyloidogenic pathway,
are seen in peripheral blood mononuclear cells of AD
patients and increased BACE1 promoter accessibility are
associated with increased histone H3 acetylation. These
findings are supported by other observations showing
aberrant histone acetylation levels in animal models of AD
[169]. Interestingly, there is some evidence that dysregula-
tion of histone H4 lysine 12 (H4K12) acetylation is impli-
cated in learning impairment in aged mice. Peleg and
colleagues [170] observed that differential gene expression
and abnormal H4 acetylation were associated with im-
paired memory function in contextual fear conditioning in
aged mice. Interestingly, these deficits were counteracted
by the application of HDAC inhibitors into the hippocam-
pus [170]. Importantly, chronic systemic inhibition of
HDAC reverts the cognitive deficit observed in APPswe/
PS1dE9 transgenic mice in the contextual fear condition-
ing model [171]. Unfortunately, the identity of the specific
HDAC(s) that is responsible for the memory impairments
remains unknown because these studies have mostly used
non-selective HDAC inhibitors.
More recent studies have indicated that HDAC2, cru-
cially involved in the regulation of memory and synaptic
plasticity, might be directly implicated [172]. Gräff and
collaborators investigated the role of HDAC2 in AD [173].
Using CK-p25 mice as model for AD-like neurodegenera-
tion, they found a significant increase of HDAC2 in the
hippocampus and prefrontal cortex of these mice. In con-
trast, no significant changes in HDAC2 expression were
detected in the amygdala, an area not affected by neurode-
generation in this animal model. When these authors in-
vestigated the functional impact HDAC2 dysregulation,
they found that H2bK5, H3K14, H4K5 and H4K12 were
all hypoacetylated in CK-p25 mice. Importantly, increased
HDAC2 binding and hypoacetylation negatively correlated
with activated RNA Polymerase II binding and mRNA ex-
pression in genes related to learning, memory and synap-
tic plasticity [173]. These observations were confirmed
by HDAC2 knockdown, which successfully restored syn-
aptic plasticity and cognitive performance in CK-p25
mice. In addition, Gräff and colleagues [173] investigated
the effects of two neurotoxic stimuli associated with AD,
hydrogen peroxide and Aβ, on HDAC2 expression in
primary hippocampal neurons. They found that these
noxious stimuli increased HDAC2 levels in cells, an event
likely resulting from glucocorticoid receptor (NR3C1) ac-
tivation in response to the neurotoxic stimuli, thus linking
AD hallmarks to aberrant epigenetic regulation possibly
mediated by NR3C1. Finally, Gräff and colleagues [173]validated their findings in postmortem human brain
samples from sporadic AD cases at different Braak stages.
These experiments revealed that HDAC2 levels are signifi-
cantly increased in the hippocampus and entorhinal cor-
tex, areas known to be affected in AD. Moreover, HDAC2
levels were elevated in all Braak stages, including I and II,
indicating that deleterious HDAC2 activity might be one
of the earlier events in the development of AD.
AD and microRNAs
Apart from their involvement in regulating neurogenesis
in normal conditions mentioned in previous sections,
miRNAs have also been shown to be involved in AD
pathogenesis. We and others have recently reviewed the
experimental evidence supporting this conclusion [127],
so we only discuss some relevant examples here. For in-
stance, miR-15, miR-16, miR-132 and miR-497 have
been associated with tau regulation, whereas miR-106a,
miR-106b, miR-107, miR-124, miR-137, miR-153, miR-
195 and miR-520c have been linked to APP metabolism
and Αβ production [174]. More specifically, a role for
miR-132 in the regulation of alternative splicing of tau
exon 10 has been demonstrated by studying its repres-
sion of the polypyrimidine tract binding protein 2
(PTBP2) transcript. This repression interfered with the
physiological phosphorylation of tau, thus linking aber-
rant miR-132 functioning to possible disease state [175].
In the same study, members of the miR-16 family (miR-
16, miR-15, miR-195 and miR-497) were identified as
regulators of ERK1 and therefore tau phosphorylation in
neuronal cells in vitro, including primary rat neurons.
An additional link between miR-16 expression and AD
pathology was introduced by Liu and colleagues [176].
In this study, miR-16 overexpression reduced APP levels
in the brains of senescence-accelerated mouse prone 8
(SAMP8) mice, another animal model of age-related be-
havioral deterioration and AD-associated neurodegenera-
tion that displays deficits in learning and memory [177].
Regulation of Aβ production further implicates miRNA
function in AD via different mechanisms. For instance,
endogenous miR-106a, miR-153, and miR-520c downreg-
ulate APP levels in human neurons by directly targeting
the 3′ UTR of the APP mRNA [178,179] and thus redu-
cing Aβ levels. Suppression of BACE1 translation by miR-
195 and miR-124 also reduces Aβ production [180,181],
while miR-137 and miR-181c indirectly regulate Αβ pro-
duction via modulation of serine palmitoyltransferase
(SPT) levels [182]. Lastly, the expression of certain miR-
NAs is affected by the presence of Aβ. miR-106b expres-
sion appears to be induced in APPswe/PS1dE9 brains due
to increased Aβ42 oligomers [183], whereas miR-9 and
miR-181c are downregulated in cultured hippocampal
neurons exposed to Aβ, providing another link to the
pathogenesis of AD [184].
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AD are also involved in other neurodegenerative diseases,
such as Mild Cognitive Impairment (MCI) or Parkinson’s
Disease (PD), some seem to be more specific to AD itself.
Recently, Leidinger and colleagues pinpointed a ‘12-
miRNA signature’ in AD using next generation sequen-
cing (NGS) to trace miRNAs from blood samples of 44
AD patients and 22 age-matched healthy controls [185].
The signature consisted of miRNAs that were differen-
tially expressed strictly in AD, including miR-26a, −26b,
−103a, −107, −112, −151a, −161, −532, −1285, −5010, let-
7d and let-7f, thereby providing a tool to distinguish AD
from other neurodegenerative diseases with a reasonable
accuracy [185]. Of note, many of these 12 miRNAs may
have distinct roles in neurodevelopmental pathways, such
as neurite outgrowth, synaptic formation and neuronal
migration, portraying the complex nature of AD and its
implications in neuronal development.
AD, Epigenetics and adult neurogenesis
Epigenetics and neurogenesis are areas of interest to AD,
both from a pathophysiological as well as for a treatment
perspective. These fields have, however, generally been
investigated separately in relation to AD, despite the cru-
cial role of epigenetic regulation in normal neurogenesis.
As discussed above, DNA methylation is crucial for NSC
fate determination, differentiation and migration, specif-
ically implicating DNMT1 and DNMT3a [61,62]. How-
ever, how changes in their levels of expression or activity
could be linked to AD pathogenesis or progression
remains largely unknown. Interestingly, chronic stress,
an environmental factor linked to an increased risk to
develop AD [186], increases DNMT3a expression in the
nucleus accumbens in rodents [187]. Moreover, the ob-
servation that brain SAM [152], 5-hmC and 5-mC levels
[156] are drastically decreased in AD patients suggests
that differentiation and migration of NSCs is impaired in
end stage AD. Furthermore, decreased levels of DNA
methylation in AD may interfere with MBD1 binding,
which is important for newborn neuron survival and
differentiation [64]. Indeed, most studies in mouse
models of AD found decreased differentiation and sur-
vival of NSCs [21]. Various others, however, detected an
AD-associated increase in proliferation, which could be
considered a compensatory mechanism [132,134].
Investigations of the use of the HDAC inhibitor VPA
as a potential treatment for AD have highlighted alter-
ations in the intricate balance between proliferation and
differentiation required for neurogenesis. While VPA
seems to reduce NSC proliferation [89], it induces differ-
entiation of neural progenitor cells, specifically enhan-
cing the generation of new neurons, and suppresses
progression towards the astrocyte and oligodendrocytes
lineages [91]. Considering the detection of significantlydecreased levels of histone acetylation in the temporal
lobe of AD patients [167], it appears that histone acetyl-
ation may be impaired in AD. This impairment in
histone acetylation hampers synaptic development in the
hippocampus, which may in part explain the ability of
VPA to improve memory deficits in animal models of
AD [188].
Ogawa and colleagues [189] observed that neurons
vulnerable to neurodegeneration in AD display signs of
cell cycle activation, but fail to proliferate. They investi-
gated this phenomenon and found that the phosphoryl-
ation of histone H3, a histone modification crucial for
chromosome compaction during cell division, was in-
creased, but appeared to be anomalously located in the
neural cytoplasm. This ectopic localization of an epigen-
etic modification crucial for cell proliferation suggests
that abnormal nuclear transport might play a role in the
epigenetic regulation of neurogenesis in AD. In support
of this hypothesis, Mastroeni and colleagues [190] re-
cently found DNMT1 and RNA polymerase II to be
abnormally sequestered in the cytoplasm in AD brains.
Importantly, their observations points towards an Aβ-
induced reduction in the expression of Ras-related
Nuclear protein (RAN), a protein crucially involved in
nucleocytoplasmic transport, as a major contribution to
the apparently malfunctioning nucleocytoplasmic trans-
port in AD.
Future perspectives
There is no perfect animal model for sporadic AD to
date, and those that exist mostly resemble rare familial
variants of AD [191]. Nevertheless, animal models have
and will certainly continue to play an important role in
AD research [192,193]. Although sporadic AD is much
less understood, recent evidence discussed in previous
sections, suggests that epigenetic mechanisms may be
involved in aspects of the etiology of AD [194]. There-
fore, it might be fruitful to develop animal models of
sporadic AD based on modulations of the cellular epi-
genetic machinery [195]. Such models could be achieved
through the introduction of genetic mutations in genes
encoding proteins or miRNAs that are involved in epi-
genetic regulation, pharmacologic induced dysregulation
of the epigenetic machinery, or through RNA interfer-
ence of components of the epigenetic apparatus. They
may reflect the etiology of sporadic AD in the sense that
they could include environmental factors, such as early
or chronic stress.
A highly promising new addition to modeling tech-
niques available for AD and an alternative to animal
models are induced pluripotent stem cells (iPSCs). The
procedure to produce stem cell-like cells from mouse
fibroblasts was developed in 2006 by Takahashi and
Yamanaka [196] and a year later they reported about
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technique allows for the de-differentiation and repro-
gramming of somatic cells into iPSCs through the
expression of a specific set of transcription factors (e.g.
octamer-binding transcription factor 4 [OCT], SRY-
related HMG-box gene 2 [SOX2], Krüppel-like factor 4
[KLF4] and cMYC) that induce the expression of pluri-
potency related genes and suppress lineage-associated
genes. These iPSCs resemble embryonic stem cells (ESCs),
in the sense that they can proliferate indefinitely and have
the potential to differentiate into any type of cell [198]. Al-
though this technique is still very time consuming and has
a low throughput, it allows for a unique way of modeling
elements of AD; through the generation of actual AD
neurons from patient-derived iPSCs. Furthermore, this
method allows to model sporadic AD, without the need of
specific disease-inducing genetic mutations and the
creation of transgenic animal models. However, in terms
of models that resemble or mimic epigenetic mechanism
linked to AD, it is worth noting that reprogramming of
somatic cells into iPSCs implies a significant resetting of
their epigenetic information [199].
Despite ongoing discussions about the exact nature of
iPSCs, the best procedure to generate them, genetic
stability, reproducibility of the resulting cell line and
how well re-differentiated iPSCs resemble the target
cells, some interesting discoveries have been done with
AD patient-derived iPSCs [200]. One study, using iPSC-
derived purified neurons from familial (caused by a du-
plication of the APP gene) and sporadic AD patients and
non-demented controls, found that especially for familial
AD, and to a lesser extend sporadic AD neurons dis-
played higher amounts of Aβ, phospho-tau and active
glycogen synthase kinase-3β (GSK-3β), all pathological
markers of AD [201]. Remarkably, GSK-3β activity con-
trols the expression of O(6)-methylguanine DNA meth-
yltransferase (MGMT) a methyltransferase which repairs
DNA damage specific to O(6)-position of guanine
[202,203]. Another study induced a neuronal phenotype
in human isolated fibroblasts from familial AD patients
(with PS1 or PS2 mutations) by transducing them with
Brn2, Ascl1, Myt1l and NeuroD1 [204]. These induced
neurons (iNs), exhibited aberrant APP processing and
localization, paired with increased Aβ production, when
compared to those derived from non-demented controls.
Using cells from AD patients to model the disease may
offer unique insights into how AD neurons function ab-
normally, or how they might be more vulnerable to cer-
tain environmental factors associated with AD etiology.
An extension of this approach has led to the generation
of induced neural progenitor-like cells (iNPCs), which
might have enhanced potential for practical applications
to treat neurodegenerative disorders [205]. Nevertheless,
it is important to keep in mind the limitations of thesemodels, as they might fail to recapitulate, or lose during
their generation, epigenetic aberrations that are poten-
tially crucial for disease onset and progression and that
may be induced by culture conditions, unknown envir-
onmental or age-related factors.
In conclusion, in the future, animal models of familial
and specifically of sporadic AD, such as the anti-nerve
growth factor (AD11) transgenic mice [206] may benefit
from incorporating some of the key concepts demon-
strated in the literature reviewed in this article, specific-
ally considering the plethora of epigenetic changes and
changes in expression of components of the cellular epi-
genetic machinery associated with AD we discussed. In
particular, epigenetic changes are of crucial importance
in adult NSCs, and the incorporation of information re-
garding epigenetic changes in current AD models could
advance our understanding of the potential role of NSCs
and adult hippocampal neurogenesis in the pathophysi-
ology of AD.
Abbreviations
5-caC: 5-carboxylcytosine; 5-fC: 5-formylcytosine; 5-hmC: 5-
hydroxymethylcytosine; 5-mC: 5-methylcytosine; Aβ: β-amyloid; ADAM: A
disintegrin and metalloproteinase; GSK-3β: Glycogen synthase kinase-3β;
AICDA: Activation-induced cytidine deaminase; APOBEC: Apolipoprotein
B mRNA editing enzyme, catalytic polypeptide-like protein;
AraC: Arabinofuranosyl Cytidine; AZA: 5-azacytidine; bHLH: Basic helix-loop-
helix; BrdU: 5-bromo-2′-deoxyuridine; ChIP: Chromatin immunoprecipitation;
CMV-GFP: Cytomegalovirus-green fluorescent protein; DAC: 5-aza-2′-
deoxycytidine; DCX: Doublecortin; DG: Dentate gyrus; Dlx2: Distal-less
homeobox 2; DNMT: DNA methyltransferase; DNA MeDIP: DNA
immunoprecipitation; EGF: Epidermal growth factor; EGFR: Epidermal growth
factor receptor; ESC: Embryonic stem cell; FGF2: Fibroblast growth factor 2;
FGFR: Fibroblast growth factor receptor; Fzd: Frizzled; Gadd45: Growth arrest
and DNA-damage-inducible 45; GCL: Granule cell layer; GFAP: Glial fibrillary
acidic protein; GSK3β: Glycogen synthase kinase 3β; HAT: Histone acetyl
transferase; HDAC: Histone de-acetylase; HMT: Histone methyltransferase;
HDM: Histone demethylase; H2A: Histone 2A; H2B: Histone 2B; H3: Histone 3;
H3K27me3: H3K27 tri-methylation; H3K4me3: H3K4 tri-methylation;
H4: Histone 4; iPSC: Induced pluripotent stem cell; iN: Induced neuron;
iNPC: Induced neural progenitor-like cell; KLF4: Krüppel-like factor 4; LEF/
TCF: Lymphoid enhancer binding factor/T-cell-specific transcription factor;
LTP: Long-term potentiation; MAML: Mastermind-like 1; MBD: Methyl-CpG
binding domain; MCAO: Middle cerebral artery occlusion; MeCP2: Methyl-
CpG-binding protein 2; MEDIP: Methylated DNA Immunoprecipitation;
MiRNA: MicroRNA; Mll1: Mixed-lineage leukemia 1 protein; NaB: Sodium
butyrate; NFT: Neurofibrillary tangle; NICD: Notch intracellular domain;
NPC: Neural progenitor cell; NSC: Neural stem cell; OB: Olfactory bulb;
OCT4: Octamer-binding transcription factor 4; PcG: Polycomb-group;
PTBP2: Polypyrimidine tract binding protein 2; Ptc: Patched; Qkf: Querkopf;
RAN: Ras-related nuclear protein; RBP-J: Recombination signal binding
protein for immunoglobulin kappa J region; RMS: Rostral migratory stream;
SEZ: Subependymal zone; SGZ: Subgranular zone; Shh: Sonic hedgehog;
SiRNA: small interfering RNA; Smo: Smoothened; Sox2: Sex determining
region Y (SRY)-box 2; SPT: Serine palmitoyltransferase; SVZ: Subventricular
zone; SAHA: Suberoylanilide hydroxamic acid; TET: Ten-eleven translocation;
TrxG: Trithorax-group; TSA: Trichostatin-A; VPA: Valproic acid.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CPF, EB, DLHH, BPFR designed the manuscript, and all authors were involved
in writing the manuscript. All authors read and approved the final
manuscript.
Fitzsimons et al. Molecular Neurodegeneration 2014, 9:25 Page 17 of 21
http://www.molecularneurodegeneration.com/content/9/1/25Acknowledgements
Funding has been provided by the Internationale Stichting Alzheimer
Onderzoek (ISAO), grant number 07551 and 11532 (D.L.A.vdH.), by the ISAO
grant number 09552 and 13515, and the Netherlands Organization for
Scientific Research (NWO), grant number 916.11.086 (Veni Award) (B.P.F.R.),
the Maastricht University Medical Centre + (Koostra Talent Fellowship) (R.L.)
and the NWO VIDI grant H64.09.016 to CPF.
Author details
1Center for Neuroscience, Swammerdam Institute for Life Sciences, University
of Amsterdam, SciencePark 904, 1098XH Amsterdam, The Netherlands.
2Department of Translational Neuroscience, School of Mental Health and
Neuroscience (MHENS), Maastricht University, Maastricht, the Netherlands.
3Department Psychiatry, Brain Center Rudolf Magnus, University Medical
Center Utrecht, Utrecht, The Netherlands. 4School of Pharmaceutical Sciences
of Ribeirão Preto, University of São Paulo, São Paulo, Brazil. 5University of
Exeter Medical School, RILD Level 4, Barrack Road, University of Exeter,
Devon, UK. 6Department of Psychiatry and Neuropsychology, School for
Mental Health and Neuroscience, Maastricht University Medical Centre, P.O.
Box 616, 6200 MD Maastricht, The Netherlands.
Received: 10 May 2014 Accepted: 6 June 2014
Published: 25 June 2014References
1. Lim DA, Huang YC, Alvarez-Buylla A: The adult neural stem cell niche:
lessons for future neural cell replacement strategies. Neurosurg Clin N Am
2007, 18:81–92.
2. Eriksson PS, Perfilieva E, Björk-Eriksson T, Alborn AM, Nordborg C, Peterson DA,
Gage FH: Neurogenesis in the adult human hippocampus. Nat Med 1998,
4:1313–1317.
3. Gage FH: Mammalian neural stem cells. Science (80-) 2000, 287:1433–1438.
4. Garzón-Muvdi T, Quiñones-Hinojosa A: Neural stem cell niches and
homing: recruitment and integration into functional tissues. ILAR J 2009,
51:3–23.
5. Van den Driesche S, Sharpe RM, Saunders PTK, Mitchell RT: Regulation of
the germ stem cell niche as the foundation for adult spermatogenesis:
A role for miRNAs? Semin Cell Dev Biol 2014, 29:76–83.
6. Januschke J, Näthke I: Stem cell decisions: A twist of fate or a niche
market? Semin Cell Dev Biol. in press.
7. Shihabuddin LS, Horner PJ, Ray J, Gage FH: Adult spinal cord stem cells
generate neurons after transplantation in the adult dentate gyrus.
J Neurosci 2000, 20:8727–8735.
8. Battista D, Ferrari CC, Gage FH, Pitossi FJ: Neurogenic niche modulation by
activated microglia: transforming growth factor beta increases
neurogenesis in the adult dentate gyrus. Eur J Neurosci 2006, 23:83–93.
9. Wurmser AE, Palmer TD, Gage FH: Cellular interactions in the stem cell
niche. Science 2004, 304:1253–1255.
10. Palmer TD, Willhoite AR, Gage FH: Vascular niche for adult hippocampal
neurogenesis. J Comp Neurol 2000, 425:479–494.
11. Mirshekar-Syahkal B, Fitch SR, Ottersbach K: From greenhouse to garden:
The changing soil of the hematopoietic stem cell microenvironment
during development. Stem Cells. in press.
12. Ghiaur G, Yegnasubramanian S, Perkins B, Gucwa JL, Gerber JM, Jones RJ:
Regulation of human hematopoietic stem cell self-renewal by the
microenvironment’s control of retinoic acid signaling. Proc Natl Acad Sci
U S A 2013, 110:16121–16126.
13. Chen S, Lewallen M, Xie T: Adhesion in the stem cell niche: biological
roles and regulation. Development 2013, 140:255–265.
14. Oatley JM, Brinster RL: The germline stem cell niche unit in mammalian
testes. Physiol Rev 2012, 92:577–595.
15. Zhao C, Deng W, Gage FH: Mechanisms and functional implications of
adult neurogenesis. Cell 2008, 132:645–660.
16. Ma DK, Marchetto MC, Guo JU, Ming G, Gage FH, Song H: Epigenetic
choreographers of neurogenesis in the adult mammalian brain.
Nat Neurosci 2010, 13:1338–1344.
17. Rotschafer JH, Hu S, Little M, Erickson M, Low WC, Cheeran MCJ:
Modulation of neural stem/progenitor cell proliferation during
experimental Herpes Simplex encephalitis is mediated by differential
FGF-2 expression in the adult brain. Neurobiol Dis 2013, 58:144–155.18. Acosta S, Jernberg J, Sanberg CD, Sanberg PR, Small BJ, Gemma C, Bickford
PC: NT-020, a natural therapeutic approach to optimize spatial memory
performance and increase neural progenitor cell proliferation and
decrease inflammation in the aged rat. Rejuvenation Res 2010, 13:581–588.
19. Lazarov O, Marr RA: Neurogenesis and Alzheimer’s disease: at the
crossroads. Exp Neurol 2010, 223:267–281.
20. Ohab J, Fleming S: A neurovascular niche for neurogenesis after stroke.
J Neurosci 2006, 26:13007–13016.
21. Mu Y, Gage FH: Adult hippocampal neurogenesis and its role in
Alzheimer’s disease. Mol Neurodegener 2011, 6:85.
22. Winner B, Kohl Z, Gage FH: Neurodegenerative disease and adult
neurogenesis. Eur J Neurosci 2011, 33:1139–1151.
23. Kaneko N, Sawamoto K: Adult neurogenesis and its alteration under
pathological conditions. Neurosci Res 2009, 63:155–164.
24. Ming G-L, Song H: Adult neurogenesis in the mammalian brain: significant
answers and significant questions. Neuron 2011, 70:687–702.
25. Mu Y, Lee SW, Gage FH: Signaling in adult neurogenesis. Curr Opin Neurobiol
2010, 20:416–423.
26. Alvarez-Buylla A, Lim DA: For the long run: maintaining germinal niches
in the adult brain. Neuron 2004, 41:683–686.
27. Ma DK, Ming G-L, Song H: Glial influences on neural stem cell development:
cellular niches for adult neurogenesis. Curr Opin Neurobiol 2005, 15:514–520.
28. Doetsch F, Caillé I, Lim DA, García-Verdugo JM, Alvarez-Buylla A: Subventricular
zone astrocytes are neural stem cells in the adult mammalian brain.
Cell 1999, 97:703–716.
29. Lim DA, Alvarez-Buylla A: Interaction between astrocytes and adult
subventricular zone precursors stimulates neurogenesis. Proc Natl Acad
Sci U S A 1999, 96:7526–7531.
30. Kempermann G, Jessberger S, Steiner B, Kronenberg G: Milestones of
neuronal development in the adult hippocampus. Trends Neurosci 2004,
27:447–452.
31. Brandt MD, Jessberger S, Steiner B, Kronenberg G, Reuter K, Bick-Sander A,
Behrens W, Von Der Kempermann G: Transient calretinin expression
defines early postmitotic step of neuronal differentiation in adult
hippocampal neurogenesis of mice. Mol Cell Neurosci 2003, 24:603–613.
32. Seidenfaden R, Desoeuvre A, Bosio A, Virard I, Cremer H: Glial conversion of
SVZ-derived committed neuronal precursors after ectopic grafting into
the adult brain. Mol Cell Neurosci 2006, 32:187–198.
33. Jablonska B, Aguirre A, Raymond M, Szabo G, Kitabatake Y, Sailor K a, Ming
G-L, Song H, Gallo V: Chordin-induced lineage plasticity of adult SVZ
neuroblasts after demyelination. Nat Neurosci 2010, 13:541–550.
34. Shen Y, Mishra R, Mani S, Meiri, Karina F: Both cell-autonomous and cell
non-autonomous functions of GAP-43 are required for normal patterning
of the cerebellum in vivo. Cerebellum 2008, 7:451–466.
35. Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, Vincent P,
Pumiglia K, Temple S: Endothelial cells stimulate self-renewal and expand
neurogenesis of neural stem cells. Science 2004, 304:1338–1340.
36. Tavazoie M, Van der Veken L, Silva-Vargas V, Louissaint M, Colonna L, Zaidi B,
Garcia-Verdugo JM, Doetsch F: A specialized vascular niche for adult neural
stem cells. Cell Stem Cell 2008, 3:279–288.
37. Culver JC, Vadakkan TJ, Dickinson ME: A specialized microvascular domain
in the mouse neural stem cell niche. PLoS One 2013, 8:e53546.
38. Goldberg JS, Hirschi KK: Diverse roles of the vasculature within the neural
stem cell niche. Regen Med 2009, 4:879–897.
39. Ramírez-Castillejo C, Sánchez-Sánchez F, Andreu-Agulló C, Ferrón S,
Aroca-Aguilar J, Sánchez P, Mira H, Escribano J, Fariñas I: Pigment
epithelium–derived factor is a niche signal for neural stem cell renewal.
Nat Neurosci 2006, 9:331–339.
40. Gómez-Gaviro MV, Scott CE, Sesay AK, Matheu A, Booth S, Galichet C,
Lovell-Badge R: Betacellulin promotes cell proliferation in the neural stem
cell niche and stimulates neurogenesis. Proc Natl Acad Sci U S A 2012,
109:1317–1322.
41. Mirzadeh Z, Merkle FT, Soriano-Navarro M, Garcia-Verdugo JM, Alvarez-Buylla A:
Neural stem cells confer unique pinwheel architecture to the ventricular
surface in neurogenic regions of the adult brain. Cell Stem Cell 2008,
3:265–278.
42. Doetsch F, Alvarez-Buylla A: Network of tangential pathways for neuronal
migration in adult mammalian brain. Proc Natl Acad Sci U S A 1996,
93:14895–14900.
43. Sanai N, Nguyen T, Ihrie R, Mirzadeh Z, Tsai H, Wong M, Gupta N, Berger M,
Huang E, Garcia-Verdugo J, Rowitch D, Alvarez-Buylla A: Corridors of
Fitzsimons et al. Molecular Neurodegeneration 2014, 9:25 Page 18 of 21
http://www.molecularneurodegeneration.com/content/9/1/25migrating neurons in the human brain and their decline during infancy.
Nature 2011, 478:382–386.
44. Whitman MC, Fan W, Rela L, Rodriguez-Gil DJ, Greer CA: Blood vessels form
a migratory scaffold in the rostral migratory stream. J Comp Neurol 2009,
516:94–104.
45. Lacar B, Herman P, Hartman NW, Hyder F, Bordey A: S phase entry of
neural progenitor cells correlates with increased blood flow in the
young subventricular zone. PLoS One 2012, 7:e31960.
46. Miyamoto N, Tanaka R, Zhang N, Shimura H, Onodera M, Mochizuki H,
Hattori N, Urabe T: Crucial role for Ser133-phosphorylated form of cyclic
AMP-responsive element binding protein signaling in the differentiation
and survival of neural progenitors under chronic cerebral hypoperfusion.
Neuroscience 2009, 162:525–536.
47. Sierra A, Encinas JM, Deudero JJP, Chancey JH, Enikolopov G, Overstreet-
Wadiche LS, Tsirka SE, Maletic-Savatic M: Microglia shape adult
hippocampal neurogenesis through apoptosis-coupled phagocytosis.
Cell Stem Cell 2010, 7:483–495.
48. Gebara E, Sultan S, Kocher-Braissant J, Toni N: Adult hippocampal neurogenesis
inversely correlates with microglia in conditions of voluntary running and
aging. Front Neurosci 2013, 7:145.
49. Mann JR: Epigenetics and memigenetics. Cell Mol Life Sci 2014, 71:1117–1122.
50. Bird A: Perceptions of epigenetics. Nature 2007, 447:396–398.
51. Hsieh J, Eisch AJ: Epigenetics, hippocampal neurogenesis, and
neuropsychiatric disorders: unraveling the genome to understand the
mind. Neurobiol Dis 2010, 39:73–84.
52. Handel AE, Ebers GC, Ramagopalan SV: Epigenetics: molecular
mechanisms and implications for disease. Trends Mol Med 2010, 16:7–16.
53. Hu X-L, Wang Y, Shen Q: Epigenetic control on cell fate choice in neural
stem cells. Protein Cell 2012, 3:278–290.
54. Ariff IM, Mitra A, Basu A: Epigenetic regulation of self-renewal and fate
determination in neural stem cells. J Neurosci Res 2012, 90:529–539.
55. Chen T, Ueda Y, Dodge JE, Wang Z, Li E: Establishment and Maintenance
of Genomic Methylation Patterns in Mouse Embryonic Stem Cells by
Dnmt3a and Dnmt3b. Mol Cell Biol 2003, 23:5594–5605.
56. Jones P a, Liang G: Rethinking how DNA methylation patterns are
maintained. Nat Rev Genet 2009, 10:805–811.
57. Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird a P, Jaenisch R:
Non-CpG methylation is prevalent in embryonic stem cells and may be
mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A 2000,
97:5237–5242.
58. Feil R, Fraga MF: Epigenetics and the environment: emerging patterns
and implications. Nat Rev Genet 2011, 13:97–109.
59. Lucassen PJ, Naninck EFG, van Goudoever JB, Fitzsimons C, Joels M, Korosi
A: Perinatal programming of adult hippocampal structure and function;
emerging roles of stress, nutrition and epigenetics. Trends Neurosci 2013,
36:621–631.
60. Covic M, Karaca E, Lie DC: Epigenetic regulation of neurogenesis in the
adult hippocampus. Heredity (Edinb) 2010, 105:122–134.
61. Singh R, Shiue K, Schomberg D, Zhou F: Cellular epigenetic modifications
of neural stem cell differentiation. Cell Transplant 2009, 18:1197–1211.
62. Wu H, Coskun V, Tao J, Xie W, Ge W, Yoshikawa K, Li E, Zhang Y, Sun YE:
Dnmt3a-dependent nonpromoter DNA methylation facilitates
transcription of neurogenic genes. Science (80- ) 2010, 329:444–448.
63. Chouliaras L, van den Hove DLA, Kenis G, Dela Cruz J, Lemmens MAM, van
Os J, Steinbusch HWM, Schmitz C, Rutten BPF: Caloric restriction
attenuates age-related changes of DNA methyltransferase 3a in mouse
hippocampus. Brain Behav Immun 2011, 25:616–623.
64. Zhao X, Ueba T, Christie BR, Barkho B, McConnell MJ, Nakashima K, Lein ES,
Eadie BD, Willhoite AR, Muotri AR, Summers RG, Chun J, Lee K-F, Gage FH:
Mice lacking methyl-CpG binding protein 1 have deficits in adult
neurogenesis and hippocampal function. Proc Natl Acad Sci U S A 2003,
100:6777–6782.
65. Li X, Barkho BZ, Luo Y, Smrt RD, Santistevan NJ, Liu C, Kuwabara T,
Gage FH, Zhao X: Epigenetic regulation of the stem cell mitogen Fgf-2
by Mbd1 in adult neural stem/progenitor cells. J Biol Chem 2008,
283:27644–27652.
66. Zheng W, Nowakowski RS, Vaccarino FM: Fibroblast growth factor 2 is
required for maintaining the neural stem cell pool in the mouse brain
subventricular zone. Dev Neurosci 2004, 26:181–196.
67. Smrt RD, Eaves-Egenes J, Barkho BZ, Santistevan NJ, Zhao C, Aimone JB,
Gage FH, Zhao X: Mecp2 deficiency leads to delayed maturation andaltered gene expression in hippocampal neurons. Neurobiol Dis 2007,
27:77–89.
68. Kohyama J, Kojima T, Takatsuka E, Yamashita T, Namiki J, Hsieh J, Gage FH:
Epigenetic regulation of neural cell differentiation plasticity in the adult
mammalian brain. PLoS One 2008, 105:18012–18017.
69. Tsujimura K, Abematsu M, Kohyama J, Namihira M, Nakashima K: Neuronal
differentiation of neural precursor cells is promoted by the methyl-CpG-
binding protein MeCP2. Exp Neurol 2009, 219:104–111.
70. Ausió J, Paz AM D, Esteller M: MeCP2: the long trip from a chromatin
protein to neurological disorders. Trends Mol Med. in press.
71. Skene PJ, Illingworth RS, Webb S, Kerr ARW, James KD, Turner DJ, Andrews
R, Bird AP: Neuronal MeCP2 is expressed at near histone-octamer levels
and globally alters the chromatin state. Mol Cell 2010, 37:457–468.
72. Bedogni F, Rossi RL, Galli F, Cobolli Gigli C, Gandaglia A, Kilstrup-Nielsen C,
Landsberger N: Rett syndrome and the urge of novel approaches to
study MeCP2 functions and mechanisms of action. Neurosci Biobehav Rev.
in press.
73. Guo JU, Su Y, Zhong C, Ming G, Song H: Hydroxylation of 5-
methylcytosine by TET1 promotes active DNA demethylation in the
adult brain. Cell 2011, 145:423–434.
74. Van den Hove DLA, Chouliaras L, Rutten BPF: The role of 5-
hydroxymethylcytosine in aging and Alzheimer’s disease: current status
and prospects for future studies. Curr Alzheimer Res 2012, 9:545–549.
75. Hahn M a, Qiu R, Wu X, Li AX, Zhang H, Wang J, Jui J, Jin S-G, Jiang Y, Pfeifer
GP, Lu Q: Dynamics of 5-hydroxymethylcytosine and chromatin marks in
Mammalian neurogenesis. Cell Rep 2013, 3:291–300.
76. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y:
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and
5-carboxylcytosine. Science 2011, 333:1300–1303.
77. Raiber E-A, Beraldi D, Ficz G, Burgess HE, Branco MR, Murat P, Oxley D,
Booth MJ, Reik W, Balasubramanian S: Genome-wide distribution of
5-formylcytosine in embryonic stem cells is associated with
transcription and depends on thymine DNA glycosylase. Genome Biol
2012, 13:R69.
78. He Y-F, Li B-Z, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, Sun Y,
Li X, Dai Q, Song C-X, Zhang K, He C, Xu G-L: Tet-mediated formation of
5-carboxylcytosine and its excision by TDG in mammalian DNA. Science
2011, 333:1303–1307.
79. Matsubara M, Tanaka T, Terato H, Ohmae E, Izumi S, Katayanagi K, Ide H:
Mutational analysis of the damage-recognition and catalytic mechanism
of human SMUG1 DNA glycosylase. Nucleic Acids Res 2004, 32:5291–5302.
80. Barreto G, Schäfer A, Marhold J, Stach D, Swaminathan SK, Handa V,
Döderlein G, Maltry N, Wu W, Lyko F, Niehrs C: Gadd45a promotes
epigenetic gene activation by repair-mediated DNA demethylation.
Nature 2007, 445:671–675.
81. Ma DK, Jang M-H, Guo JU, Kitabatake Y, Chang M-L, Pow-Anpongkul N,
Flavell R a, Lu B, Ming G-L, Song H: Neuronal activity-induced Gadd45b
promotes epigenetic DNA demethylation and adult neurogenesis.
Science (80-) 2009, 323:1074–1077.
82. Rai K, Huggins IJ, James SR, Karpf AR, Jones DA, Cairns BR: DNA demethylation
in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45.
Cell 2008, 135:1201–1212.
83. Schmitz K-M, Schmitt N, Hoffmann-Rohrer U, Schäfer A, Grummt I, Mayer C:
TAF12 recruits Gadd45a and the nucleotide excision repair complex to
the promoter of rRNA genes leading to active DNA demethylation.
Mol Cell 2009, 33:344–353.
84. Tan L, Xiong L, Xu W, Wu F, Huang N, Xu Y, Kong L, Zheng L, Schwartz L,
Shi Y, Shi YG: Genome-wide comparison of DNA hydroxymethylation in
mouse embryonic stem cells and neural progenitor cells by a new
comparative hMeDIP-seq method. Nucleic Acids Res 2013, 41:e84.
85. Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, Hore T a, Marques
CJ, Andrews S, Reik W: Dynamic regulation of 5-hydroxymethylcytosine in
mouse ES cells and during differentiation. Nature 2011, 473:398–402.
86. Khare T, Pai S, Koncevicius K, Pal M, Kriukiene E, Liutkeviciute Z, Irimia M, Jia
P, Ptak C, Xia M, Tice R, Tochigi M, Moréra S, Nazarians A, Belsham D, Wong
AHC, Blencowe BJ, Wang SC, Kapranov P, Kustra R, Labrie V, Klimasauskas S,
Petronis A: 5-hmC in the brain is abundant in synaptic genes and shows
differences at the exon-intron boundary. Nat Struct Mol Biol 2012,
19:1037–1043.
87. Gavin DP, Chase KA, Sharma RP: Active DNA demethylation in post-mitotic
neurons: A reason for optimism. Neuropharmacology 2013, 75:233–245.
Fitzsimons et al. Molecular Neurodegeneration 2014, 9:25 Page 19 of 21
http://www.molecularneurodegeneration.com/content/9/1/2588. Sun G, Fu C, Shen C, Shi Y: Histone deacetylases in neural stem cells and
induced pluripotent stem cells. J Biomed Biotechnol 2011, 2011:1–6.
89. Sun G, Yu RT, Evans RM, Shi Y: Orphan nuclear receptor TLX recruits
histone deacetylases to repress transcription and regulate neural stem
cell proliferation. Proc Natl Acad Sci U S A 2007, 104:15282–15287.
90. Zhou Q, Dalgard CL, Wynder C, Doughty ML: Histone deacetylase inhibitors
SAHA and sodium butyrate block G1-to-S cell cycle progression in
neurosphere formation by adult subventricular cells. BMC Neurosci 2011,
12:50.
91. Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH: Histone deacetylase
inhibition-mediated neuronal differentiation of multipotent adult neural
progenitor cells. Proc Natl Acad Sci U S A 2004, 101:16659–16664.
92. Siebzehnrubl F a, Buslei R, Eyupoglu IY, Seufert S, Hahnen E, Blumcke I:
Histone deacetylase inhibitors increase neuronal differentiation in adult
forebrain precursor cells. Exp Brain Res 2007, 176:672–678.
93. Jawerka M, Colak D, Dimou L, Spiller C, Lagger S, Montgomery RL, Olson EN,
Wurst W, Göttlicher M, Götz M: The specific role of histone deacetylase 2
in adult neurogenesis. Neuron Glia Biol 2010, 6:93–107.
94. Merson TD, Dixon MP, Collin C, Rietze RL, Bartlett PF, Thomas T, Voss AK:
The transcriptional coactivator Querkopf controls adult neurogenesis.
J Neurosci 2006, 26:11359–11370.
95. Qureshi IA, Mehler MF: The emerging role of epigenetics in stroke.
Arch Neurol 2011, 68:294–302.
96. Fasano CA, Phoenix TN, Kokovay E, Lowry N, Elkabetz Y, Dimos JT,
Lemischka IR, Studer L, Temple S: Bmi-1 cooperates with Foxg1 to
maintain neural stem cell self-renewal in the forebrain. Genes Dev 2009,
23:561–574.
97. Zencak D, Lingbeek M, Kostic C, Tekaya M, Tanger E, Hornfeld D, Jaquet M,
Munier FL, Schorderet DF, van Lohuizen M, Arsenijevic Y: Bmi1 loss
produces an increase in astroglial cells and a decrease in neural stem
cell population and proliferation. J Neurosci 2005, 25:5774–5783.
98. Bruggeman SWM, Valk-Lingbeek ME, van der Stoop PPM, Jacobs JJL,
Kieboom K, Tanger E, Hulsman D, Leung C, Arsenijevic Y, Marino S, van
Lohuizen M: Ink4a and Arf differentially affect cell proliferation and
neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 2005,
19:1438–1443.
99. Lim D a, Huang Y-C, Swigut T, Mirick AL, Garcia-Verdugo JM, Wysocka J, Ernst P,
Alvarez-Buylla A: Chromatin remodelling factor Mll1 is essential for
neurogenesis from postnatal neural stem cells. Nature 2009, 458:529–533.
100. Schouten M, Buijink MR, Lucassen PJ, Fitzsimons CP: New neurons in aging
brains: molecular control by small non-coding RNAs. Front Neurosci 2012,
6:1–13.
101. Kozomara A, Griffiths-Jones S:miRBase: annotating high confidence microRNAs
using deep sequencing data. Nucleic Acids Res 2014, 42:D68–D73.
102. Volvert M-L, Rogister F, Moonen G, Malgrange B, Nguyen L: MicroRNAs
tune cerebral cortical neurogenesis. Cell Death Differ 2012, 19:1573–1581.
103. Liu N, Landreh M, Cao K, Abe M, Hendriks G-J, Kennerdell JR, Zhu Y,
Wang L-S, Bonini NM: The microRNA miR-34 modulates ageing and
neurodegeneration in Drosophila. Nature 2012, 482:519–523.
104. Fineberg SK, Datta P, Stein CS, Davidson BL: MiR-34a represses Numbl in
murine neural progenitor cells and antagonizes neuronal differentiation.
PLoS One 2012, 7:e38562.
105. Aranha MM, Santos DM, Solá S, Steer CJ, Rodrigues CMP: miR-34a regulates
mouse neural stem cell differentiation. PLoS One 2011, 6:e21396.
106. Agostini M, Tucci P, Steinert JR, Shalom-Feuerstein R, Rouleau M, Aberdam D,
Forsythe ID, Young KW, Ventura A, Concepcion CP, Han Y-C, Candi E, Knight
RA, Mak TW, Melino G: microRNA-34a regulates neurite outgrowth, spinal
morphology, and function. Proc Natl Acad Sci U S A 2011, 108:21099–21104.
107. Lukiw WJ: Micro-RNA speciation in fetal, adult and Alzheimer’s disease
hippocampus. Neuroreport 2007, 18:297–300.
108. Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K,
Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM,
Roses AD, Richards CA: Identification of miRNA changes in Alzheimer’s
disease brain and CSF yields putative biomarkers and insights into
disease pathways. J Alzheimers Dis 2008, 14:27–41.
109. Pogue AI, Percy ME, Cui J-G, Li YY, Bhattacharjee S, Hill JM, Kruck TPA, Zhao Y,
Lukiw WJ: Up-regulation of NF-kB-sensitive miRNA-125b and miRNA-146a
in metal sulfate-stressed human astroglial (HAG) primary cell cultures.
J Inorg Biochem 2011, 105:1434–1437.
110. Lee YS, Kim HK, Chung S, Kim K-S, Dutta A: Depletion of human micro-RNA
miR-125b reveals that it is critical for the proliferation of differentiated cellsbut not for the down-regulation of putative targets during differentiation.
J Biol Chem 2005, 280:16635–16641.
111. Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, Paganelli A, Di
Marcotullio L, Caffarelli E, Screpanti I, Bozzoni I, Gulino A: Concerted
microRNA control of Hedgehog signalling in cerebellar neuronal
progenitor and tumour cells. EMBO J 2008, 27:2616–2627.
112. Cui Y, Xiao Z, Han J, Sun J, Ding W, Zhao Y, Chen B, Li X, Dai J: MiR-125b
orchestrates cell proliferation, differentiation and migration in neural
stem/progenitor cells by targeting Nestin. BMC Neurosci 2012, 13:116.
113. Le MTN, Xie H, Zhou B, Chia PH, Rizk P, Um M, Udolph G, Yang H, Lim B,
Lodish HF: MicroRNA-125b promotes neuronal differentiation in human
cells by repressing multiple targets. Mol Cell Biol 2009, 29:5290–5305.
114. Pathania M, Torres-Reveron J, Yan L, Kimura T, Lin TV, Gordon V, Teng Z-Q,
Zhao X, Fulga TA, Van Vactor D, Bordey A: miR-132 enhances dendritic
morphogenesis, spine density, synaptic integration, and survival of
newborn olfactory bulb neurons. PLoS One 2012, 7:e38174.
115. Nudelman AS, DiRocco DP, Lambert TJ, Garelick MG, Le J, Nathanson NM,
Storm DR: Neuronal activity rapidly induces transcription of the
CREB-regulated microRNA-132, in vivo. Hippocampus 2010, 20:492–498.
116. Hansen KF, Sakamoto K, Wayman GA, Impey S, Obrietan K: Transgenic
miR132 alters neuronal spine density and impairs novel object
recognition memory. PLoS One 2010, 5:e15497.
117. Yang D, Li T, Wang Y, Tang Y, Cui H, Tang Y, Zhang X, Chen D, Shen N, Le
W: miR-132 regulates the differentiation of dopamine neurons by
directly targeting Nurr1 expression. J Cell Sci 2012, 125(Pt 7):1673–1682.
118. Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL,
Mandel G, Goodman RH: microRNA-132 regulates dendritic growth and
arborization of newborn neurons in the adult hippocampus. Proc Natl
Acad Sci U S A 2010, 107:20382–20387.
119. Abuhatzira L, Makedonski K, Kaufman Y, Razin A, Shemer R: MeCP2
deficiency in the brain decreases BDNF levels by REST/CoREST-mediated
repression and increases TRKB production. Epigenetics 2007, 2:214–222.
120. Remenyi J, Hunter CJ, Cole C, Ando H, Impey S, Monk CE, Martin KJ, Barton GJ,
Hutvagner G, Arthur JSC: Regulation of the miR-212/132 locus by MSK1 and
CREB in response to neurotrophins. Biochem J 2010, 428:281–291.
121. Cheng L-C, Pastrana E, Tavazoie M, Doetsch F: miR-124 regulates adult
neurogenesis in the subventricular zone stem cell niche. Nat Neurosci
2009, 12:399–408.
122. Zhao C, Sun G, Li S, Shi Y: A feedback regulatory loop involving microRNA-9
and nuclear receptor TLX in neural stem cell fate determination. Nat Struct
Mol Biol 2009, 16:365–371.
123. Zhao C, Sun G, Li S, Lang M-F, Yang S, Li W, Shi Y: MicroRNA let-7b regulates
neural stem cell proliferation and differentiation by targeting nuclear
receptor TLX signaling. Proc Natl Acad Sci U S A 2010, 107:1876–1881.
124. Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, Li Y, Lee-Messer C,
Dolmetsch RE, Tsien RW, Crabtree GR: MicroRNA-mediated conversion of
human fibroblasts to neurons. Nature 2011, 476:228–231.
125. Smrt RD, Szulwach KE, Pfeiffer RL, Li X, Guo W, Pathania M, Teng Z-Q, Luo Y,
Peng J, Bordey A, Jin P, Zhao X: MicroRNA miR-137 regulates neuronal
maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells 2010,
28:1060–1070.
126. Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, Lin L, Santistevan NJ, Li W, Zhao X,
Jin P: Cross talk between microRNA and epigenetic regulation in adult
neurogenesis. J Cell Biol 2010, 189:127–141.
127. Van den Hove DL, Kompotis K, Lardenoije R, Kenis G, Mill J, Steinbusch HW,
Lesch K-P, Fitzsimons CP, De Strooper B, Rutten BPF: Epigenetically
regulated microRNAs in Alzheimer’s disease. Neurobiol Aging 2014,
35:731–745.
128. Liu C, Teng Z, Santistevan N, Szulwach K: Epigenetic regulation of miR-184
by MBD1 governs neural stem cell proliferation and differentiation.
Cell Stem Cell 2010, 6:433–444.
129. American Psychiatric Association: Diagnostic and statistical manual of
mental disorders (4th ed., text rev.). 2000.
130. Maccioni RB, Muñoz JP, Barbeito L: The molecular bases of Alzheimer’s disease
and other neurodegenerative disorders. Arch Med Res 2001, 32:367–381.
131. Fuster-Matanzo A, Llorens-Martín M, Hernández F, Avila J: Role of
neuroinflammation in adult neurogenesis and Alzheimer disease:
therapeutic approaches. Mediators Inflamm 2013, 2013:1–9.
132. Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA:
Increased hippocampal neurogenesis in Alzheimer’s disease. Proc Natl
Acad Sci U S A 2004, 101:343–347.
Fitzsimons et al. Molecular Neurodegeneration 2014, 9:25 Page 20 of 21
http://www.molecularneurodegeneration.com/content/9/1/25133. Boekhoorn K, Joels M, Lucassen PJ: Increased proliferation reflects glial
and vascular-associated changes, but not neurogenesis in the presenile
Alzheimer hippocampus. Neurobiol Dis 2006, 24:1–14.
134. Perry EK, Johnson M, Ekonomou A, Perry RH, Ballard C, Attems J:
Neurogenic abnormalities in Alzheimer’s disease differ between stages
of neurogenesis and are partly related to cholinergic pathology.
Neurobiol Dis 2012, 47:155–162.
135. Crews L, Adame A, Patrick C, Delaney A, Pham E, Rockenstein E, Hansen L,
Masliah E: Increased BMP6 levels in the brains of Alzheimer’s disease
patients and APP transgenic mice are accompanied by impaired
neurogenesis. J Neurosci 2010, 30:12252–12262.
136. Li B, Yamamori H, Tatebayashi Y, Shafit-Zagardo B, Tanimukai H, Chen S,
Iqbal K, Grundke-Iqbal I: Failure of neuronal maturation in Alzheimer
disease dentate gyrus. J Neuropathol Exp Neurol 2008, 67:78–84.
137. Waldau B, Shetty AK: Behavior of neural stem cells in the Alzheimer brain.
Cell Mol Life Sci 2008, 65:2372–2384.
138. Taupin P: Adult neurogenesis, neural stem cells and Alzheimer’s disease:
developments, limitations, problems and promises. Curr Alzheimer Res
2009, 6:461–470.
139. Brinton RD, Wang JM: Therapeutic potential of neurogenesis for
prevention and recovery from Alzheimer’s disease: allopregnanolone as
a proof of concept neurogenic agent. Curr Alzheimer Res 2006, 3:185–190.
140. Ziabreva I, Perry E, Perry R, Minger SL, Ekonomou A, Przyborski S, Ballard C:
Altered neurogenesis in Alzheimer’s disease. J Psychosom Res 2006,
61:311–316.
141. Lilja AM, Röjdner J, Mustafiz T, Thomé CM, Storelli E, Gonzalez D, Unger-
Lithner C, Greig NH, Nordberg A, Marutle A: Age-dependent neuroplasti-
city mechanisms in Alzheimer Tg2576 mice following modulation of
brain amyloid-β levels. PLoS One 2013, 8:e58752.
142. Li G, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K, Halabisky B,
Deng C, Mahley RW, Huang Y: GABAergic interneuron dysfunction impairs
hippocampal neurogenesis in adult apolipoprotein E4 knockin mice.
Cell Stem Cell 2009, 5:634–645.
143. Brasnjevic I, Lardenoije R, Schmitz C, Kolk N, Dickstein DL, Takahashi H, Hof PR,
Steinbusch HWM, Rutten BPF: Region-specific neuron and synapse loss in
the hippocampus of APPSL/PS1 knock-in mice. Transl Neurosci 2013, 4:8–19.
144. Chen Q, Nakajima A, Choi SH, Xiong X, Sisodia SS, Tang Y-P: Adult neurogenesis
is functionally associated with AD-like neurodegeneration. Neurobiol Dis 2008,
29:316–326.
145. Morgenstern NA, Giacomini D, Lombardi G, Castaño EM, Schinder AF:
Delayed dendritic development in newly generated dentate granule
cells by cell-autonomous expression of the amyloid precursor protein.
Mol Cell Neurosci 2013, 56:298–306.
146. Zhao C, Teng EM, Summers RG, Ming G-L, Gage FH: Distinct morphological
stages of dentate granule neuron maturation in the adult mouse
hippocampus. J Neurosci 2006, 26:3–11.
147. West RL, Lee JM, Maroun LE: Hypomethylation of the amyloid precursor
protein gene in the brain of an Alzheimer’s disease patient. J Mol Neurosci
1995, 6:141–146.
148. Barrachina M, Ferrer I: DNA methylation of Alzheimer disease and
tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol
2009, 68:880–891.
149. Brohede J, Rinde M, Winblad B, Graff C: A DNA methylation study of the
amyloid precursor protein gene in several brain regions from patients
with familial Alzheimer disease. J Neurogenet 2010, 24:179–181.
150. Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Genda Y, Ukitsu M:
Reduction with age in methylcytosine in the promoter region −224
approximately −101 of the amyloid precursor protein gene in autopsy
human cortex. Brain Res Mol Brain Res 1999, 70:288–292.
151. Tohgi H, Utsugisawa K, Nagane Y, Yoshimura M, Ukitsu M, Genda Y: The
methylation status of cytosines in a tau gene promoter region alters
with age to downregulate transcriptional activity in human cerebral
cortex. Neurosci Lett 1999, 275:89–92.
152. Morrison LD, Smith DD, Kish SJ: Brain S-adenosylmethionine levels are severely
decreased in Alzheimer’s disease. J Neurochem 1996, 67:1328–1331.
153. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD: Epigenetic
differences in cortical neurons from a pair of monozygotic twins
discordant for Alzheimer’s disease. PLoS One 2009, 4:e6617.
154. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J:
Epigenetic changes in Alzheimer’s disease: decrements in DNA
methylation. Neurobiol Aging 2010, 31:2025–2037.155. Chouliaras L, van den Hove DLA, Kenis G, Keitel S, Hof PR, van Os J,
Steinbusch HWM, Schmitz C, Rutten BPF: Prevention of age-related
changes in hippocampal levels of 5-methylcytidine by caloric restriction.
Neurobiol Aging 2012, 33:1672–1681.
156. Chouliaras L, Mastroeni D, Delvaux E, Grover A, Kenis G, Hof PR, Steinbusch
HWM, Coleman PD, Rutten BPF, van den Hove DLA: Consistent decrease in
global DNA methylation and hydroxymethylation in the hippocampus of
Alzheimer’s disease patients. Neurobiol Aging 2013, 34:2091–2099.
157. Condliffe D, Wong A, Troakes C, Proitsi P, Patel Y, Chouliaras L, Fernandes C,
Cooper J, Lovestone S, Schalkwyk LC, Mill J, Lunnon K: Cross-region
reduction in 5-hydroxymethylcytosine in Alzheimer’s disease brain.
Neurobiol Aging. in press.
158. Chen K-L, Wang SS-S, Yang Y-Y, Yuan R-Y, Chen R-M, Hu C-J: The epigenetic
effects of amyloid-beta(1–40) on global DNA and neprilysin genes in
murine cerebral endothelial cells. Biochem Biophys Res Commun 2009,
378:57–61.
159. Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ,
Biniszkiewicz D, Jaenisch R, Laird PW, Akbarian S: DNA methylation in the
human cerebral cortex is dynamically regulated throughout the life span
and involves differentiated neurons. PLoS One 2007, 2:e895.
160. Urdinguio RG, Sanchez-Mut JV, Esteller M: Epigenetic mechanisms in
neurological diseases: genes, syndromes, and therapies. Lancet Neurol
2009, 8:1056–1072.
161. Hoyaux D, Decaestecker C, Heizmann CW, Vogl T, Schäfer BW, Salmon I, Kiss
R, Pochet R: S100 proteins in Corpora amylacea from normal human
brain. Brain Res 2000, 867:280–288.
162. Scarpa S, Fuso A, D’Anselmi F, Cavallaro RA: Presenilin 1 gene silencing by
S-adenosylmethionine: a treatment for Alzheimer disease? FEBS Lett 2003,
541:145–148.
163. Bakulski KM, Dolinoy DC, Sartor M a, Paulson HL, Konen JR, Lieberman AP,
Albin RL, Hu H, Rozek LS: Genome-wide DNA methylation differences
between late-onset Alzheimer’s disease and cognitively normal controls
in human frontal cortex. J Alzheimers Dis 2012, 29:571–588.
164. Münzel M, Globisch D, Brückl T, Wagner M, Welzmiller V, Michalakis S,
Müller M, Biel M, Carell T: Quantification of the sixth DNA base
hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl 2010,
49:5375–5377.
165. Song C-X, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, Li Y, Chen C-H, Zhang W,
Jian X, Wang J, Zhang L, Looney TJ, Zhang B, Godley LA, Hicks LM, Lahn BT,
Jin P, He C: Selective chemical labeling reveals the genome-wide
distribution of 5-hydroxymethylcytosine. Nat Biotechnol 2011, 29:68–72.
166. Morgan AR, Hamilton G, Turic D, Jehu L, Harold D, Abraham R, Hollingworth
P, Moskvina V, Brayne C, Rubinsztein DC, Lynch A, Lawlor B, Gill M,
O’Donovan M, Powell J, Lovestone S, Williams J, Owen MJ: Association
analysis of 528 intra-genic SNPs in a region of chromosome 10 linked to
late onset Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet
2008, 147B:727–731.
167. Zhang K, Schrag M, Crofton A, Trivedi R, Vinters H, Kirsch W: Targeted
proteomics for quantification of histone acetylation in Alzheimer’s
disease. Proteomics 2012, 12:1261–1268.
168. Marques SCF, Lemos R, Ferreiro E, Martins M, de Mendonça A, Santana I,
Outeiro TF, Pereira CMF: Epigenetic regulation of BACE1 in Alzheimer’s
disease patients and in transgenic mice. Neuroscience 2012, 220:256–266.
169. Gräff J, Kim D, Dobbin MM, Tsai L-H: Epigenetic regulation of gene
expression in physiological and pathological brain processes. Physiol Rev
2011, 91:603–649.
170. Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, Agis-Balboa RC,
Cota P, Wittnam JL, Gogol-Doering A, Opitz L, Salinas-Riester G, Dettenhofer M,
Kang H, Farinelli L, Chen W, Fischer A: Altered histone acetylation is
associated with age-dependent memory impairment in mice.
Science 2010, 328:753–756.
171. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh
G: Inhibitors of class 1 histone deacetylases reverse contextual memory
deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology
2010, 35:870–880.
172. Guan J-S, Haggarty SJ, Giacometti E, Dannenberg J-H, Joseph N, Gao J,
Nieland TJF, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA,
Jaenisch R, Tsai L-H: HDAC2 negatively regulates memory formation and
synaptic plasticity. Nature 2009, 459:55–60.
173. Gräff J, Rei D, Guan J-S, Wang W-Y, Seo J, Hennig KM, Nieland TJF, Fass DM,
Kao PF, Kahn M, Su SC, Samiei A, Joseph N, Haggarty SJ, Delalle I, Tsai L-H:
Fitzsimons et al. Molecular Neurodegeneration 2014, 9:25 Page 21 of 21
http://www.molecularneurodegeneration.com/content/9/1/25An epigenetic blockade of cognitive functions in the neurodegenerating
brain. Nature 2012, 483:222–226.
174. Bicchi I, Morena F, Montesano S, Polidoro M, Martino S: MicroRNAs and
Molecular Mechanisms of Neurodegeneration. Genes 2013, 4:244–263.
175. Hébert SS, Sergeant N, Buée L: MicroRNAs and the Regulation of Tau
Metabolism. Int J Alzheimers Dis 2012, 2012:1–6.
176. Liu W, Liu C, Zhu J, Shu P, Yin B, Gong Y, Qiang B, Yuan J, Peng X:
MicroRNA-16 targets amyloid precursor protein to potentially modulate
Alzheimer’s-associated pathogenesis in SAMP8 mice. Neurobiol Aging
2012, 33:522–534.
177. Takeda T: Senescence-accelerated mouse (SAM) with special references
to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem Res
2009, 34:639–659.
178. Patel N, Hoang D, Miller N, Ansaloni S, Huang Q, Rogers JT, Lee JC, Saunders
AJ: MicroRNAs can regulate human APP levels. Mol Neurodegener 2008,
3:10.
179. Long JM, Ray B, Lahiri DK: MicroRNA-153 physiologically inhibits
expression of amyloid-β precursor protein in cultured human fetal brain
cells and is dysregulated in a subset of Alzheimer disease patients.
J Biol Chem 2012, 287:31298–31310.
180. Zhu H-C, Wang L-M, Wang M, Song B, Tan S, Teng J-F, Duan D-X: MicroRNA-
195 downregulates Alzheimer’s disease amyloid-β production by targeting
BACE1. Brain Res Bull 2012, 88:596–601.
181. Fang M, Wang J, Zhang X, Geng Y, Hu Z, Rudd JA, Ling S, Chen W, Han S:
The miR-124 regulates the expression of BACE1/β-secretase correlated
with cell death in Alzheimer’s disease. Toxicol Lett 2012, 209:94–105.
182. Geekiyanage H, Chan C: MicroRNA-137/181c regulates serine
palmitoyltransferase and in turn amyloid β, novel targets in sporadic
Alzheimer’s disease. J Neurosci 2011, 31:14820–14830.
183. Wang H, Liu J, Zong Y, Xu Y, Deng W, Zhu H, Liu Y, Ma C, Huang L, Zhang
L, Qin C: miR-106b aberrantly expressed in a double transgenic mouse
model for Alzheimer’s disease targets TGF-β type II receptor. Brain Res
2010, 1357:166–174.
184. Schonrock N, Humphreys DT, Preiss T, Götz J: Target gene repression
mediated by miRNAs miR-181c and miR-9 both of which are down-
regulated by amyloid-β. J Mol Neurosci 2012, 46:324–335.
185. Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller SC, Frese K, Haas J,
Ruprecht K, Paul F, Stähler C, Lang CJ, Meder B, Bartfai T, Meese E, Keller A:
A blood based 12-miRNA signature of Alzheimer disease patients.
Genome Biol 2013, 14:R78.
186. Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA: Chronic
psychological distress and risk of Alzheimer’s disease in old age.
Neuroepidemiology 2006, 27:143–153.
187. LaPlant Q, Vialou V, Covington HE, Dumitriu D, Feng J, Warren BL, Maze I,
Dietz DM, Watts EL, Iñiguez SD, Koo JW, Mouzon E, Renthal W, Hollis F,
Wang H, Noonan MA, Ren Y, Eisch AJ, Bolaños CA, Kabbaj M, Xiao G, Neve
RL, Hurd YL, Oosting RS, Fan G, Morrison JH, Nestler EJ: Dnmt3a regulates
emotional behavior and spine plasticity in the nucleus accumbens. Nat
Neurosci 2010, 13:1137–1143.
188. Qing H, He G, Ly PTT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X,
Chen C-H, Zhou W, Wang K, Song W: Valproic acid inhibits Abeta
production, neuritic plaque formation, and behavioral deficits in
Alzheimer’s disease mouse models. J Exp Med 2008, 205:2781–2789.
189. Ogawa O, Zhu X, Lee H-G, Raina A, Obrenovich ME, Bowser R, Ghanbari HA,
Castellani RJ, Perry G, Smith MA: Ectopic localization of phosphorylated
histone H3 in Alzheimer’s disease: a mitotic catastrophe? Acta Neuropathol
2003, 105:524–528.
190. Mastroeni D, Chouliaras L, Grover A, Liang WS, Hauns K, Rogers J,
Coleman PD: Reduced RAN expression and disrupted transport
between cytoplasm and nucleus; a key event in Alzheimer’s disease
pathophysiology. PLoS One 2013, 8:e53349.
191. Delacourte A, Buée L: Animal models of Alzheimer’s disease: a road full of
pitfalls. Psychol Neuropsychiatr Vieil 2005, 3:261–270.
192. German DC, Eisch AJ: Mouse models of Alzheimer’s disease: insight into
treatment. Rev Neurosci 2004, 15:353–369.
193. Chouliaras L, Sierksma ASR, Kenis G, Prickaerts J, Lemmens MAM, Brasnjevic
I, van Donkelaar EL, Martinez-Martinez P, Losen M, De Baets MH, Kholod N,
van Leeuwen F, Hof PR, van Os J, Steinbusch HWM, van den Hove DLA,
Rutten BPF: Gene-environment interaction research and transgenic
mouse models of Alzheimer’s disease. Int J Alzheimers Dis 2010, 2010:1–27.194. Chouliaras L, Rutten BPF, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os
J, Steinbusch HWM, van den Hove DLA: Epigenetic regulation in the
pathophysiology of Alzheimer’s disease. Prog Neurobiol 2010, 90:498–510.
195. Kwok JBJ: Role of epigenetics in Alzheimer’s and Parkinson’s disease.
Epigenomics 2010, 2:671–682.
196. Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse
embryonic and adult fibroblast cultures by defined factors. Cell 2006,
126:663–676.
197. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka
S: Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell 2007, 131:861–872.
198. Verma A, Verma N: Induced pluripotent stem cells and promises of
neuroregenerative medicine. Neurol India 2011, 59:555–557.
199. Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich
LIR, Yabuuchi A, Takeuchi A, Cunniff KC, Hongguang H, McKinney-Freeman
S, Naveiras O, Yoon TJ, Irizarry RA, Jung N, Seita J, Hanna J, Murakami P,
Jaenisch R, Weissleder R, Orkin SH, Weissman IL, Feinberg AP, Daley GQ:
Epigenetic memory in induced pluripotent stem cells. Nature 2010,
467:285–290.
200. Wojda U, Kuznicki J: Alzheimer’s disease modeling: ups, downs, and
perspectives for human induced pluripotent stem cells. J Alzheimers Dis
2013, 34:563–588.
201. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van
Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH,
Remes AM, Koo EH, Goldstein LSB: Probing sporadic and familial
Alzheimer’s disease using induced pluripotent stem cells. Nature 2012,
482:216–220.
202. Pyko IV, Nakada M, Sabit H, Teng L, Furuyama N, Hayashi Y, Kawakami K,
Minamoto T, Fedulau AS, Hamada J: Glycogen synthase kinase 3β
inhibition sensitizes human glioblastoma cells to temozolomide by
affecting O6-methylguanine DNA methyltransferase promoter
methylation via c-Myc signaling. Carcinogenesis 2013, 34:2206–2217.
203. Christmann M, Verbeek B, Roos WP, Kaina B: O(6)-Methylguanine-DNA
methyltransferase (MGMT) in normal tissues and tumors: enzyme activity,
promoter methylation and immunohistochemistry. Biochim Biophys Acta
1816, 2011:179–190.
204. Qiang L, Fujita R, Yamashita T, Angulo S, Rhinn H, Rhee D, Doege C, Chau L,
Aubry L, Vanti WB, Moreno H, Abeliovich A: Directed conversion of
Alzheimer’s disease patient skin fibroblasts into functional neurons.
Cell 2011, 146:359–371.
205. Tian C, Liu Q, Ma K, Wang Y, Chen Q, Ambroz R, Klinkebiel DL, Li Y, Huang
Y, Ding J, Wu J, Zheng JC: Characterization of induced neural progenitors
from skin fibroblasts by a novel combination of defined factors. Sci Rep
2013, 3:1345.
206. Capsoni S: β-Amyloid Plaques in a Model for Sporadic Alzheimer’s
Disease Based on Transgenic Anti-Nerve Growth Factor Antibodies.
Mol Cell Neurosci 2002, 21:15–28.
doi:10.1186/1750-1326-9-25
Cite this article as: Fitzsimons et al.: Epigenetic regulation of adult
neural stem cells: implications for Alzheimer’s disease. Molecular
Neurodegeneration 2014 9:25.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
